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ABSTRACT 
During the last few decades, the treatment of sialolithiasis and chronic recurrent 
sialadenitis has shifted more toward a minimally invasive approach. The 
development of salivary endoscopy (sialendoscopy) has allowed visual access into 
the salivary duct system to diagnose and treat various duct conditions. Favorable 
results have been achieved in the treatment of sialolithiasis and duct strictures, 
and the symptoms of chronic sialadenitis seem to respond to this novel 
intervention as well.  
The aim of the present study was to assess the results of sialendoscopy in the 
treatment of obstructive and chronic sialadenitis, the complications of 
sialendoscopy, and tolerability of sialendoscopy under local anesthesia (LA). In 
addition, the health-related quality of life (HRQoL) of sialadenitis patients and 
the costs of treatment were investigated.  
We evaluated the medical records of all (n=228) patients who underwent 
sialendoscopy at the Department of Otorhinolaryngology – Head and Neck 
Surgery at Helsinki University Hospital (HUS) between January 2011 and 
December 2013. Using these data, we analyzed the main endoscopic findings and 
treatment results.  
To assess the patient experience and compliance in sialendoscopy, 89 LA 
patients completed a questionnaire designed by the authors; on it, the patients 
rated their sensations (pain, discomfort, and nervousness) before, during, and 
after the operation using a scale from “none” to “major”.  
In the prospective study, 49 patients with chronic recurrent parotitis without 
sialoliths were collected. They underwent sialendoscopy and were randomized to 
receive either a concurrent intraductal injection of isotonic saline solution or 125 
mg of hydrocortisone (1:1).  
To evaluate the incidence and nature of complications associated with 
sialendoscopy, we prospectively recruited 118 patients with 140 sialendoscopies 
between October 2015 and December 2016. Patient data, treatment failures, and 
complications were recorded in a database and analyzed.  
In the fifth study, all patients (n=260) who had a sialendoscopy at our 
institution between January 2014 and May 2016 were identified from a surgical 
database, and the direct hospital costs were retrospectively evaluated from one 
year before to one year after the sialendoscopy. In addition, the 15D health-related 
quality of life (15D HRQoL) questionnaire and a survey exploring the use of health 
care services during the preceding three months were mailed to the patients 
preoperatively and at 3 and 12 months postoperatively. 
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The sialoliths were successfully removed in a majority of patients, but removal 
was possible with the endoscopic technique only in a minority. The symptoms 
resolved or improved in most patients after successful sialolith removal or 
stricture dilatation. Improvement was also seen in patients with inflammatory 
changes, but the symptoms relapsed quite often in this group. A single-dose 
steroid injection concomitant to sialendoscopy provided no additional benefit for 
the symptoms of chronic recurrent parotitis in this study. 
In most cases, both diagnostic and interventional sialendoscopy were well 
tolerated under LA or under local anesthesia with sedation (LAS), with reasonably 
low patient-reported discomfort and pain. The complications of sialendoscopy 
were usually related to interventional procedures, and infection was the most 
common complication. Treatment costs were higher in sialolithiasis patients than 
in patients with other diagnoses. In sialolithiasis patients, the improvement of 
HRQoL was noticed at three months postoperatively.  
In conclusion, according to this study, sialolithiasis patients benefit from the 
sialendoscopic intervention but combined techniques are often needed. 
Symptoms of chronic recurrent parotitis seem to improve after sialendoscopy, but 
total resolution of symptoms remains rare. Sialendoscopy is a safe and well-
tolerated procedure, but not free of complications. It improves HRQoL, at least in 
patients with sialolithiasis in a short-term fashion.  
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SUMMARY IN FINNISH 
Viimeisen parin vuosikymmenen aikana sylkikivitaudin ja kroonisen 
sylkirauhastulehduksen hoito on muuttunut vähemmän invasiiviseksi ja käyttöön 
on tullut nk. elimen säästävä hoito. Tähystysinstrumenttien kehityksen myötä 
hyvänlaatuisten sylkirauhasvaivojen diagnostiikka on tarkentunut ja 
tiehyttukosten hoito mahdollistunut. Hyviä tuloksia on saavutettu niin sylkikivien 
kuin tiehytahtaumienkin hoidossa. Myös kroonisen sylkirauhastulehduksen 
oireet lievittyvät usein ainakin väliaikaisesti sylkirauhasen tähystyksen myötä. 
Tämän väitöskirjatyön tarkoituksena oli selvittää sylkirauhasen tähystyksen 
hoidollisia tuloksia ahtauttavan ja kroonisen sylkirauhastulehduksen osalta, 
tarkastella tähystykseen liittyviä komplikaatioita ja toimenpiteen siedettävyyttä 
paikallispuudutuksessa. Lisäksi tutkittiin potilaiden elämänlaatua ja 
sylkikivitaudin sekä sylkirauhastulehduksen hoitokustannuksia.  
Kaikkien 1/2011-12/2013 Helsingin yliopistollisessa sairaalassa korva-, nenä- 
ja kurkkutautien poliklinikalla sylkirauhasen tähystyksessä olleiden potilaiden 
(228 potilasta) sairauskertomustiedot analysoitiin. Pääasialliset 
tähystyslöydökset ja hoitotulokset rekisteröitiin. 
Kahdeksankymmentäyhdeksän potilasta, joille sylkirauhasen tähystys tehtiin 
paikallispuudutuksessa tai kevyessä sedaatiossa, täyttivät kyselykaavakkeen, 
jossa arvioitiin toimenpiteen aiheuttamaa kipua ja epämukavuutta.  
Etenevään tutkimukseen kerättiin 49 kroonisesta, toistuvasta 
korvasylkirauhastulehduksesta kärsivää potilasta. Heille tehtiin sylkirauhasen 
tähystys ja potilaat satunnaistettiin saamaan tähystyksen yhteydessä tiehyeen 
sisäisesti annosteltua isotonista keittosuolaliuosta tai 125mg hydrokortisonia 
(1:1).  
Toiseen etenevään tutkimukseen rekrytoitiin 118 potilasta, joille tehtiin 
yhteensä 140 sylkirauhasen tähystystä tutkimusaikana 10/2015-12/2016. 
Potilastiedot, epäonnistuneet toimenpiteet ja komplikaatiot rekisteröitiin.  
Viidennessä osatyössä kaikkien potilaiden, joille oli tehty klinikassamme 
sylkirauhasen tähystys 1/2014-5/2016, sairaskertomustiedot haettiin 
potilasrekisteristä ja potilaiden hoitokustannukset selvitettiin kahden vuoden 
ajalta (vuosi ennen tähystystä ja vuosi tähystyksen jälkeen). Lisäksi 15D-
elämänlaatukysely ja kysely käytetyistä sairaalapalveluista postitettiin potilaille 
ennen toimenpidettä sekä kolmen ja 12 kuukauden kuluttua toimenpiteestä.  
Sylkikivet saatiin poistettua onnistuneesti suurimmalta osalta potilaista (77-
84%), mutta ainoastaan pienellä osalla potilaista (12-23%) tämä onnistui 
pelkästään tähystimen ja kori-instrumentin avulla ilman tiehyeen avaamista. 
Oireet vähenivät tai parantuivat valtaosalla potilaista onnistuneen sylkikiven 
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poiston (95%) sekä tiehytahtauman avaamisen (79%) jälkeen. Myös potilailla, 
joilla löydöksenä oli tiehyen tulehdusmuutoksia, oireet helpottivat, mutta uusivat 
kohtuullisen usein (38%). Tiehyeen sisäisestä, tähystyksen yhteydessä 
annostellusta kortisoniannoksesta ei ollut lisäapua. 
Sylkirauhasen tähystys todettiin tutkimuksessamme varsin hyvin siedetyksi 
toimenpiteeksi sekä paikallispuudutuksessa että kevyessä sedaatiossa tehtynä. 
Tutkimuksessa esiin tulleet komplikaatiot liittyivät yleensä tähystykseen, jossa 
tehtiin samalla hoitotoimenpide ja bakteeritulehdus oli yleisimmin havaittu 
komplikaatio. Hoitokustannukset olivat korkeammat sylkikivipotilailla muihin 
potilaisiin verrattuna. Sylkikivipotilaiden elämänlaatu parani 15D-kyselyn 
perusteella toimenpiteen jälkeen ainakin lyhyellä aikavälillä. 
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1 INTRODUCTION 
Obstructive sialadenitis is the most common non-neoplastic condition of the 
major salivary glands. Obstruction decreases saliva flow with various sequelae 
and, for example, predisposes to bacterial infections. The symptoms are usually 
unilateral recurrent painful swelling exacerbated during meals, and the 
submandibular gland is the most frequently affected site (Butt 2012). The main 
cause of obstruction is sialolithiasis followed by strictures and stenosis (Nahlieli 
et al. 2006a, Ngy et al. 2007). Chronic inflammation is more common in the 
parotid gland. The inflamed gland is swollen and soreness might occur. Juvenile 
recurrent parotitis occurs in children, while Sjögren’s syndrome and some other 
autoimmune diseases may cause inflammation and swelling of the salivary glands 
in adults. The etiology of sialadenitis often remains unknown (Motamed et al. 
2003, Butt 2012). 
Traditionally, symptomatic ductal or hilar stones have been managed by 
transoral incision and extirpation, while intraparenchymal and non-palpable 
stones have required removal of the gland. Treatment of chronic sialadenitis has 
been challenging when the conservative methods with nonsteroidal anti-
inflammatory drugs (NSAID), gland massage, and hydration have failed. Ductal 
ligation and intraductal administration of different medicines have been 
attempted to induce atrophy of the affected gland (Bowling et al. 1994, Wang et 
al. 1998). Tympanic neurectomy has been used for the treatment of chronic 
recurrent parotitis with variable results, while sialadenectomy has been the last 
treatment option (Motamed et al. 2003). 
Development of sialendoscopy throughout the 1990s and early 2000s has 
allowed the intraluminal visualization of the ductal system, permitting precise 
diagnostics, and minimally invasive treatment of salivary stones and strictures 
with a high success rate (Nahlieli & Baruchin 2000, Marchal et al. 2002, Koch et 
al. 2012a). There is also evidence that sialendoscopy can relieve the symptoms of 
chronic sialadenitis by flushing the mucus plugs and dilating the duct (Vashishta 
& Gillespie 2013) and even enhancing salivary flow and reducing xerostomia 
(Karagozoglu et al. 2018). In recent years, the use of sialendoscopy has spread 
worldwide, and meanwhile, the rate of sialadenectomies performed because of 
sialadenitis has reduced (Rasmussen et al. 2016). Sialendoscopy has been 
considered a safe and well-tolerated procedure. However, while the complications 
are usually minor, they still may necessitate re-operations or hospitalization.  
During the last decade, greater interest has focused on the patients’ health-
related quality of life (HRQoL). Chronic recurrent sialadenitis causes symptoms 
that can continue for years or even decades and that are typically quite disruptive. 
Introduction 
14 
Thus, it could be assumed that the patients’ HRQoL is decreased, but only a very 
limited amount of information exists in the literature. HRQoL can be measured 
either with generic or disease-specific questionnaires. The lack of a validated, 
sensitive questionnaire to assess the salivary gland-related quality of life has 
recently been recognized (Gillespie et al. 2015, Aubin-Pouliot et al. 2016b). 
Although several case series and retrospective studies represent the efficacy of 
sialendoscopy in the treatment of obstructive sialadenitis, many procedure-
related issues and guidelines still warrant further examination. The aim of the 
present study was to assess treatment outcomes of sialadenitis and sialolithiasis 
with sialendoscopy, to evaluate patient compliance and complications related to 
this technique as well as HRQoL of the treated patients and, further, to 
understand the costs related to the treatment of sialadenitis using a 
sialendoscopic approach. 
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2 REVIEW OF THE LITERATURE 
2.1 Salivary glands 
Human major salivary glands include the pairs of parotid, submandibular, and 
sublingual glands. Together, they are responsible for over 90% of the total saliva 
production. Additionally, about 600 to 1000 minor salivary glands locate 
throughout the oral cavity and pharynx within the submucosa. The main task of 
the salivary glands is to secrete saliva, which plays an important role in digestion 
and taste, the lubrication of food and buccal mucosa, immunity, and oral health 
(Holsinger & Bui 2007). The topographical location of major salivary glands is 
seen in Figure 1. 
2.1.1 Embryology 
The embryologic development of the salivary glands begins at six to eight weeks 
when oral ectodermal outpouching extends into the adjacent mesoderm. 
Important interactions between epithelial and mesenchymal tissues occur, 
controlling salivary gland morphogenesis. At the first stage, branched duct buds 
emerge due to repeated epithelial bud and cleft formation as a solid proliferation 
of bud-like structures invaginate toward a mesenchyme. At the second stage, the 
early lobules and duct canalization occur. Finally, the acini and intercalated ducts 
mature and the interstitial connective tissue decreases. The glands are extensively 
branched, showing differentiated terminal acinar buds, myoepithelial cells, and 
distinct ductal segments. The process is called branching morphogenesis and is 
also seen in the development of other secretory organs such as the lungs, 
pancreas, and kidneys. A capsule forms from ambient mesenchyme (Holsinger & 
Bui 2007, Varner & Nelson 2014, de Paula et al. 2017).  
2.1.2 Anatomy 
2.1.2.1 Parotid gland 
The parotid glands are the largest salivary glands in humans, weighing on average 
15 to 30 g. They are located in the preauricular region and along the posterior 
surface of the mandible. The facial nerve emerges from the stylomastoid foramen 
of the skull and enters the parotid gland at its posterior margin. It branches 
approximately 1.3 cm from the foramen and dives into the upper and lower 
division, which give rise to temporal, zygomatic, buccal, marginal mandibular, 
and cervical branches. The facial nerve divides the parotid gland into the 
superficial lobe overlying the masseter muscle and the deep lobe extending into 
Review of the literature 
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the parapharyngeal space. The superficial layer of deep cervical fascia splits to 
cover the parotid gland (Holsinger & Bui 2007). 
Stensen’s duct is the main excretory duct of the parotid gland. It arises from 
the anterior aspect of the gland, travels parallel to the zygoma over the masseter 
muscle, pierces the buccinator, and opens in the mouth at the level of the second 
upper molar tooth. It is about 5 cm in length and 0.5–1.4 mm in diameter. While 
the ostium is the narrowest part, the masseteric bend at the anterior border of the 
masseter muscle can be challenging to navigate during sialendoscopy (Zenk et al. 
1998, Horsburgh & Massoud 2013). 
The blood supply to the parotid gland comes from the branches of the external 
carotid artery, the superficial temporal and maxillary artery, and venous drainage 
is through the retromandibular vein. The secretory parasympathetic innervation 
of the parotid gland originates from the inferior salivatory nucleus and travels 
with the glossopharyngeal nerve, and via the tympanic nerve, synapsing in the 
otic ganglion with the lesser petrosal nerve and forming the auriculotemporal 
nerve, which carries parasympathetic fibers to the parotid gland. The facial nerve 
also supplies some secretory innervation to the parotid gland via the chorda 
tympani nerve. The sympathetic innervation originates from the superior cervical 
ganglion through the external carotid plexus. The sensory innervation is provided 
by the auriculotemporal nerve deriving from the mandibular branch of the 
trigeminal nerve (Holsinger & Bui 2007). 
2.1.2.2 Submandibular gland 
The submandibular glands are the second-largest pair of human salivary glands, 
weighing 7 to 16 g. They are located in submandibular triangles. The gland is 
divided into the superficial and deep lobes by the posterior edge of the mylohyoid 
muscle. Most of the gland lies caudally to the mylohyoid muscle. The deep part 
lies mostly on the mylohyoid muscle and posteriorly comes to contact with the 
hyoglossus muscle and the lingual and hypoglossal nerves. A capsule originating 
from the middle layer of the deep cervical fascia encloses the gland (Holsinger & 
Bui 2007).   
The submandibular duct arises from the superficial lobe curving over the 
posterior edge of the mylohyoid muscle into the sublingual space where it runs as 
the Wharton’s duct beneath the mucosa of the floor of the mouth, crosses the 
lingual nerve superiorly, and opens at each side of the lingual frenulum. It is 
approximately 5–6 cm in length and has a diameter of 0.5–1.5 mm (Zenk et al. 
1998, de Paula et al. 2017). 
The submandibular gland receives its blood supply from the lingual and facial 
arteries via sublingual and submental arteries, and the venous drainage is mainly 
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though the sublingual and submental veins, which drain into the lingual and facial 
veins, respectively (Holsinger & Bui 2007). Parasympathetic innervation to the 
submandibular gland is provided by the superior salivatory nucleus via the chorda 
tympani, a branch of the facial nerve, which synapses with the lingual nerve on 
the submandibular ganglion. The sympathetic innervation originates from the 
superior cervical ganglion (Holsinger & Bui 2007). 
2.1.2.3 Sublingual gland 
The sublingual glands are the smallest of the major salivary glands, weighing 2 to 
4 g. They locate anteriorly in the submucosa, superficial to the mylohyoid muscle, 
and they lack the capsule. The secretion is excreted by several small sublingual 
ducts, referred to as the ducts of Rivinus, which open directly into the floor of the 
mouth, and via duct of Bartholin, which usually fuse with the Wharton’s duct 
(Holsinger & Bui 2007).   
As in the submandibular gland, the blood supply to the sublingual gland 
comes from the sublingual and submental arteries, and the venous drainage is 
through the sublingual and submental veins. Parasympathetic innervation 
originates from the superior salivatory nucleus and travels the same path as in the 
case of the submandibular gland. Sympathetic innervation is provided from the 
superior cervical ganglion (Holsinger & Bui 2007).  
2.1.2.4 Minor salivary glands 
Minor salivary glands are located throughout the oral and oropharyngeal 
submucosa, mostly in the buccal, labial, palatal, and lingual regions. They are 1 to 
2 mm in diameter and are not encapsulated by connective tissue. Each gland has 
its own duct, which opens directly into the oral cavity. Parasympathetic 
innervation comes mostly from the lingual nerve and partly from the palatine 
nerve (Holsinger & Bui 2007). 
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Figure 1 Anatomy of major salivary glands. Artist: Elina Romppanen. 
2.1.3 Physiology 
Salivary glands are composed of acini, the secretory units that drain into 
intercalated, striated, and excretory ducts. Myoepithelial cells surround the acini 
and intercalated ducts to support saliva secretion. The surrounding connective 
tissue divides the gland into the lobules. Three types of acini are recognized: 
serous acini secreting watery saliva; mucous acini secreting viscous, mucus saliva; 
and mixed or seromucous acini, which contain components of both types. The 
parotid glands are exclusively formed by serous acini and are responsible for 
about 25% of unstimulated saliva production, but during stimulation, their role 
increases and they supply about two-thirds of saliva secretion. Submandibular 
glands, which produce about 70% of unstimulated saliva, have mixed acini, but 
the serous ones predominate, unlike in the sublingual gland. The rest of the 
unstimulated saliva is produced by sublingual glands with mixed acini and minor 
salivary glands with solely mucous acini, producing 3–4% and 1–5% of saliva flow, 
respectively (Holsinger & Bui 2007, Elluru 2010). 
A healthy adult secretes approximately 1.0–1.5 liters of saliva each day. The 
salivary production and secretion are under the control of complex neuronal 
signals by the autonomic nervous system. In general, parasympathetic 
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stimulation promotes the secretion of saliva with large volume and low protein 
contents, whereas sympathetic stimulation leads to the secretion of low volumes 
with higher protein contents. The ductal system actively participates in modifying 
the electrolyte concentration of saliva from isotonic primary saliva to a highly 
hypotonic solution and the flow rate influence for the electrolyte composition. 
Saliva is composed mainly of water, but it also contains other compounds such as 
electrolytes and mucins as well as enzymes and antimicrobial agents such as 
amylase, lipase, trypsin, lysozymes, peroxidases, lactoferrin, kallikreins, and 
immunoglobulin A. Saliva serves as a lubricant to facilitate speech, mastication, 
and swallowing, initiates food digestion, plays an important role in the sense of 
taste by carrying chemicals to the taste receptors, protects the teeth and oral 
mucosa, buffers the oral pH, and contributes to the remineralization of teeth 
(Elluru 2010).  
2.2 Infectious diseases of the salivary glands  
2.2.1 Acute suppurative sialadenitis 
Although bacterial infection may involve any of the major salivary glands, the 
parotid gland is most commonly affected, probably due to serous saliva produced 
in the parotid glands, which has a smaller amount of the protective components 
such as IgA antibodies, sialic acids, lysozymes, and mucins when compared to 
mucous saliva of submandibular or sublingual glands (Rogers &  McCaffrey 
2010).  
Acute suppurative sialadenitis presents with sudden pain and swelling, 
localized erythema, and tenderness of the affected gland and is usually unilateral. 
Purulent exudate from the duct is confronted, and the patient might have a fever 
(Peel & Seethala 2007, Rogers & McCaffrey 2010). Acute suppurative sialadenitis 
is usually caused by retrograde bacterial contamination of the salivary duct by oral 
flora. The stasis of salivary flow secondary to dehydration, post-surgical setting, 
radiation, anticholinergic medications, age or mechanical obstruction (e.g., 
sialoliths, strictures, or foreign bodies such as pieces of hair, fish bone, or food 
fragment) may allow bacterial migration into the gland. Also, diseases such as 
diabetes mellitus, periodontal disease, hypothyroidism, renal failure, and 
immunosuppression for any reason may predispose to acute sialadenitis (Peel & 
Seethala 2007, Brook 2002, Rogers & McCaffrey 2010). The hematogenic spread 
of bacteria or the transition from adjacent infection focus are rare causes 
(Scoggins et al. 2010). 
The most common bacteria cultured in acute sialadenitis is Staphylococcus 
aureus (Raad et al. 1990, Brook 2002). Streptococcal species and Haemophilus 
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influenzae are also seen. The major role of anaerobic bacteria such as 
Peptostreptococcus spp. and anaerobic gram-negative bacilli (i.e., Prevotella, 
Porphyromonas, and Fusobacterium spp) have been recognized more recently, 
and they can be found in over half the cases. Mixed infections are common (Brook 
2002). An evident-based review suggests that cephalosporins and 
fluoroquinolones display superior pharmacokinetics in saliva and cover most of 
the bacteria presented in sialadenitis, while phenoxymethylpenicillin and 
tetracyclines are not secreted in the saliva at bactericidal levels. Metronidazole 
may be a viable option in the management of anaerobes sialadenitis (Troeltzsch 
et al. 2014). Rarely, the condition can lead to abscess formation when surgical 
drainage might be necessary (Tan & Goh 2007). 
2.2.2 Viral infections of the salivary glands 
Viral sialadenitis most commonly spreads through hematogenous dissemination 
and is part of systemic disease. Typically, patients experience prodromal 
symptoms like malaise, low-grade fever, sore throat, headache, myalgia, and loss 
of appetite a few days before glandular symptoms. Glandular swelling and 
tenderness are usually bilateral, and there is no purulent discharge from the duct 
(McQuone 1999).  
Mumps has been the most common cause of acute non-suppurative parotitis 
in children and adolescents until the 1990s. Since then, widespread vaccination 
has resulted in a more than 90% decline in rates of disease. The disease is highly 
contagious and spreads through aerosol droplets from saliva and nasopharyngeal 
secretions. Parotitis is present in about 60–70% of patients and in 95% of patients 
with symptoms (Hviid et al. 2008). 
Several other viruses, such as Epstein-Barr virus, parainfluenza virus, 
influenza virus, Coxsackievirus, adenovirus, enterovirus, parvovirus, and human 
herpesvirus 6, have been related to parotitis with symptoms similar to those seen 
in mumps (McQuone 1999). In a study of 601 Finnish children and adolescents 
with mumps-like symptoms, the viral etiology was demonstrated in 84 (14%) 
patients (Davidkin et al. 2005). However, many of these viruses can also be 
detected in the saliva of asymptomatic persons.   
2.2.3 Human immunodeficiency virus (HIV)–related parotitis 
The most common salivary gland presentation among HIV-infected patients is 
painless and usually bilateral salivary gland swelling or enlargement. The 
prevalence is from 1–10% in HIV-positive individuals. Parotid glands are most 
often affected, and the state is usually secondary to the development of benign 
lymphoepithelial cysts. This condition is so unusual in the HIV-negative 
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population that cystic enlargement of the parotid glands should evoke suspicion 
of HIV infection, especially in children (Dave et al. 2007, Shanti & Aziz 2009). 
Swelling might also be related to diffusing infiltrative lymphocytosis syndrome, 
benign lymphoepithelial lesions, generalized lymphadenopathy, acute infections, 
or tumors such as lymphoma or Kaposi sarcoma in HIV-positive patients (Dave 
et al. 2007, Islam et al. 2012).  
2.3 Obstructive sialadenitis 
Obstructive sialadenitis is the most common benign inflammatory disease of the 
major salivary glands, usually presenting in the submandibular gland with 
unilateral recurrent painful swelling exacerbated during meals and sometimes 
complicated by bacterial infection (Butt 2012). Sialoliths are the main cause of 
obstructive sialadenitis, representing approximately 60–80% of all cases, 
occurring most often in submandibular glands. Strictures and stenosis are the 
second most common cause, contributing up to 15–25% of cases, and occurring 
more often in the parotid gland (Nahlieli et al. 2006a, Ngy et al. 2007, Gallo et al. 
2016). It has been suggested that in patients with swelling of unclear origin, 
strictures may produce over 50–80% of cases (Koch et al. 2005, Vashishta & 
Gillespie 2013). Strictures and stenosis might be related to surgical manipulation 
of the ductal system or sialoliths, but they might also be due to chronic 
inflammation, e.g., autoimmune diseases, chronic recurrent parotitis, radioiodine 
treatment, or radiotherapy (Baurmash 2004, Koch et al. 2012b, Kopec et al. 
2013b). 
Other causes of obstructive symptoms include mucus plugs, polyps, foreign 
bodies, external pressure due to tumors, and congenital anomalies of the duct 
(Nahlieli et al. 2006a). The first-line treatment for acute symptoms of obstructive 
sialadenitis are NSAIDs, hydration, and antibiotics in cases of suppurative 
sialadenitis. Massaging the swollen gland with pressure from the fingers along the 
duct is beneficial since it will enhance the flow of saliva and decrease the swelling 
and pain. 
2.3.1 Sialolithiasis 
Postmortem studies have shown the prevalence of sialolithiasis to be up to 1.2% 
in the general population (Rauch & Gorlin 1970). Although small stones may not 
cause symptoms, the incidence of symptomatic sialolithiasis has been estimated 
to be between 1 in 10 000–30 000 individuals per year (Escudier & McGurk 1999, 
Marchal & Dulguerov 2003, Schroder et al. 2015). About 80% of salivary stones 
occur in submandibular glands and about 20% in parotid glands. Sialoliths in 
sublingual and minor salivary glands are very rare (Huoh & Eisele 2011, Zenk et 
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al. 2012, Sigismund et al. 2015). At the time of diagnosis, the average size of 
submandibular sialoliths has been reported to be about 8.3 mm (range 1–35 mm) 
and parotid sialoliths about 6.4 mm (range 1–31 mm) (Sigismund et al. 2015), 
with an annual growth rate of about 1 mm per year (Rauch &  Gorlin 1970). 
The peak incidence of sialolithiasis is between 30 to 60 years of age and 
remains rare in the pediatric population (Lustmann et al. 1990). Male 
predominance in the patient population has been reported before, but more 
recent studies report an equal distribution between men and women (Zenk et al. 
2012, Schroder et al. 2015, Sigismund et al. 2015).  
2.3.1.1 Pathophysiology and etiology 
Sialoliths consist of varying ratios of organic and inorganic material. Although a 
few sialoliths are made up of only organic material, the majority of them are 
mainly composed of inorganic materials with an organic matrix arranged in a 
multilayer structure, including, e.g., calcium carbonates and phosphates, cellular 
debris, glycoproteins, and mucopolysaccharides (Grases et al. 2003, Rakesh et al. 
2014). 
The exact pathogenesis of sialolithiasis remains unknown, but various 
theories have been proposed. These hypotheses include the accumulation of 
microliths, retrograde migration of substances from the oral cavity, anatomical 
variations of the salivary ducts (Kraaij et al. 2014), and an altered biochemical 
composition of saliva (Grases et al. 2003, Demirhan et al. 2017). It has been 
suggested that age and secretory inactivity of the salivary gland may lead to 
increased formation of microliths, which gives rise to focal obstructive atrophy of 
the gland parenchyma and contributes to sialolith formation (Epivatianos et al. 
1987, Harrison 2009). Other investigators have proposed that food debris and 
bacteria within the oral cavity may migrate into the salivary duct and serve as a 
nidus for stone formation. This process might be facilitated by variations in the 
sphincter-like mechanism (Nahlieli & Baruchin 2000, Marchal et al. 2001c, 
Chuangqi et al. 2013). This theory has been supported by studies that have found 
bacterial gene fragments in salivary calculi with a polymerase chain reaction, 
suggesting that the bacteria might have a potential role in the pathogenesis of 
sialoliths (Teymoortash et al. 2002, Fusconi et al. 2016). The longer course of 
Wharton’s duct and the flow against gravity and the more viscous saliva with 
higher calcium concentration and alkaline pH may favor the formation of 
sialoliths in the submandibular glands (Kraaij et al. 2014). In general, it is thought 
that salivary stasis and inflammation contribute to the development of salivary 
stones (Harrison 2009). Proposed etiological factors include tobacco smoking, 
dehydration, the use of diuretics (Huoh & Eisele 2011), poor oral hygiene (Hung 
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et al. 2016), and hard water (Schroder et al. 2015), but their role remains 
controversial (Kraaij et al. 2015). 
2.3.1.2 Treatment 
The treatment of salivary stones depends on their size, shape, and location (Luers 
et al. 2011, Zenk et al. 2012). The primary goal should be the removal of the stone 
and preservation of the glandular function. Scintigraphic studies have shown that 
recovery of the secretory function is reached in most cases after stone removal 
(Makdissi et al. 2004, Su et al. 2009), and about half the submandibular glands 
showed a normal histological pattern after sialolith removal (Marchal et al. 
2001b). 
Gland-preserving treatment options include transoral stone removal 
techniques, interventional sialendoscopy, extracorporeal shockwave lithotripsy 
(ESWL), or a combination of these techniques (Iro et al. 2009). Submandibular 
stones that can be palpated up to the hilar region can be removed transorally by 
using various techniques. Zenk et al. (2001) have described an expanded duct 
excision from the papilla to the stone with hilar marsupialization, whereas 
McGurk et al. (2004) and Capaccio et al. (2011) prefer to perform an oblique 
incision to the mucosa from the papilla along the floor of mouth, bluntly dissect 
the duct, release and preserve the lingual nerve, and make a limited duct incision 
directly over the palpated stone. Also, a limited incision directly over the stone 
and blunt dissection have been used (Shashinder et al. 2011). Success rates of 
transoral submandibular stone removal vary from 79–98% (Roh & Park 2008, 
Combes et al. 2009, Iro et al. 2009, Zhang et al. 2010, Capaccio et al. 2011, Park 
et al. 2012, Zenk et al. 2012, Schapher et al. 2017). However, approximately 15% 
of residual concrements or recurrence of obstructive symptoms following surgery 
of Wharton’s duct via the transoral route have been observed in some studies 
(Zhang et al. 2010, Gerni et al. 2017). 
The role of duct marsupialization after transoral sialolith removal is 
controversial, but in a prospective, randomized, controlled study, Roh and Park 
(2008) found that sialodochoplasty had no effect on preventing symptom 
recurrence. Similar findings were observed in a cross-sectional study of 150 
patients treated with transoral sialolithectomy with or without sialodochoplasty. 
Sialodochoplasty did not affect the rate of symptom recurrence but did increase 
postoperative hypoesthesia, need for general anesthesia (GA), and operating time 
(Park et al. 2012).   
ESWL is a non-invasive method introduced in the early 1990s to fragment 
salivary stones. The shockwaves may be generated extracorporeally using 
piezoelectric or electromagnetic techniques and carried out with ultrasound 
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guidance. A large multicenter study of 2 102 cases reported complete success rates 
after ESWL treatment for parotid stones in 70% and submandibular stones in 41% 
of cases. The technique was partially successful in a further 26% of cases (Iro et 
al. 2009). The efficiency of ESWL can be enhanced by compounding it with 
sialendoscopy (Zenk et al. 2012). However, the rate of success for sialolithotripsy 
clearly decreases with the increase in stone diameter (Escudier et al. 2010).  
Sialendoscopy has improved the treatment options of sialolithiasis, and this 
technique is introduced later in the sialendoscopy paragraph.  
Submandibulectomy remains as the last treatment option for patients with 
persistent symptoms after mini-invasive treatment attempts. Studies have shown 
that the need for submandibular excision has decreased significantly after the 
development of sialendoscopy and nowadays is under 5% (Kopec et al. 2013). 
Parotidectomy is rarely performed today because of sialoliths due to its invasive 
nature, risk of complications, and the success achieved with more conservative 
approaches. 
2.4 Chronic sialadenitis 
Chronic sialadenitis most often affects the parotid glands and is characterized by 
repeated episodes of swelling and tenderness of the affected gland, which might 
slowly progress into more frequent and persistent symptoms with time (Watkin 
& Hobsley 1986). The exact pathogenesis of chronic sialadenitis is not completely 
understood, but it is likely to be multifactorial. The primary pathophysiological 
event is thought to be decreased salivary production or obstructive stagnation. As 
a result, there is insufficient salivary flow, which can lead to ascending salivary 
duct infection via the oral cavity and progress to acute bacterial infection or 
frequent opportunistic infections (Travis & Hecht 1977, Motamed et al. 2003, Butt 
2012). According to Harrison et al. (1997), the microsialoliths, also found in 
normal salivary glands, can be important in the pathophysiology of chronic 
sialadenitis, impacting the small intraglandular ducts and causing obstructive 
atrophy where the ascendant microbes can proliferate and cause further 
inflammation. Recurrent inflammatory reactions lead to strictures, sialectasis, 
ductal ectasia, fibrosis, and acinar atrophy accompanied by a lymphocytic 
infiltration. Thus, a further reduction of salivary flow follows (Travis & Hecht 
1977, Seifert 1997, Bhatty et al. 1998). Many local factors causing retardation and 
obstruction of the duct, including sialoliths, strictures, kinks, and plaques, have 
been associated with chronic sialadenitis (Zou et al. 1992, Yu et al. 2008, 
Vashishta & Gillespie 2013). However, it is often unclear whether the disease is 
the result of primary obstruction with secondary infection and inflammation or 
primary infection and/or inflammation with secondary obstruction. 
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Autoimmune diseases are responsible for a small number of chronic 
sialadenitis. Sjögren’s syndrome (SS) is the most ruling, but some other immune-
mediated diseases, such as immunoglobulin G4-related disease (IgG4-RD), 
sarcoidosis (Vourexakis et al. 2010, Ungprasert et al. 2016), granulomatosis with 
polyangiitis (Barrett 2012), and systemic lupus erythematosus (Shacham et al. 
2011), are encountered in the salivary glands. Radiation and radioiodine 
treatment may also induce inflammation and progressive damage with strictures 
and fibrosis, leading to chronic obstructive sialadenitis and hyposalivation 
(Mandel & Mandel 2003, Wu et al. 2015a, Hong et al. 2017). Baer et al. (2017) 
stated that there might be an allergic etiology in some cases of recurrent salivary 
gland swelling with eosinophil-rich mucus plugs or sialodochitis with periductal 
eosinophilic infiltration. Sometimes the recurrent parotitis of childhood can 
persist into adulthood (Shacham et al. 2009, Wang et al. 2009). The treatment of 
chronic sialadenitis should be targeted against the etiological factor, if identified, 
and the revealing of symptoms. In many cases, however, the etiology remains 
unclear. 
2.4.1 Chronic recurrent parotitis 
Chronic recurrent parotitis, also called idiopathic or non-specific parotitis, 
commonly designates chronic salivary gland inflammation without a definable 
cause. It is characterized by intermittent, mildly tender, uni- or bilateral swelling 
of the parotid gland, which might persist from days to weeks or even months 
(Nahlieli et al. 2004a). There is a female predominance, and the age distribution 
is typically 40–60 years (Seifert 1997). The etiology remains unclear, but a 
marked reduction of salivary flow usually occurs, and the secretion is viscous and 
milky (Baurmash 2004). There is an electrolyte concentration change in the acute 
stage in the parotid fluid, especially in levels of sodium and chloride, but the 
relevance of this finding remains controversial (Mandel & Baurmash 1980, 
Baurmash 2004). Also, elevated levels of some serum proteins, such as albumin 
and lactoferrin, have been measured in the acute phase. Baurmash (2004) has 
suggested that serum proteins leak into the salivary ducts and coagulate as a 
consequence of gland inflammation, thus causing obstruction, further 
inflammation, and damage. Repeated episodes of acute infections may lead to 
mucus metaplasia of the ductal epithelium, resulting in increased mucous content 
of secretion, stasis, and further inflammation (Bhatty et al. 1998). Sialography 
usually demonstrates ductal sausaging with strictures and dilations as well as 
punctate sialectasia and acinar atrophy (Wang et al. 1992).  
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2.4.2 Juvenile recurrent parotitis 
Juvenile recurrent parotitis (JRP) is a nonspecific recurrent parotid gland 
inflammation in children, and in the current era, it is the most common cause of 
parotitis in children in Western countries. The etiopathology of JRP is unclear, 
although immunodeficiency with hypogammaglobulinemia, isolated 
immunoglobulin deficiency (Marsman & Sukhai 1999, Fazekas et al. 2005), 
autoimmune diseases, an early stage of SS (Cimaz et al. 2003, Baszis et al. 2012), 
congenital  parotid malformations, infections, microbes (Ericson et al. 1991, 
Giglio et al. 1997), and genetics (Reid et al. 1998, Kolho et al. 2005) have been 
proposed. According to an epidemiological questionnaire of over 700 Finnish 
adolescents, the rate of verified episode(s) of JRP was 1.1% (Saarinen et al. 2013). 
The peak onset of symptoms is from four to six years (Kolho et al. 2005), and the 
symptoms usually resolve after puberty. The recurrent uni- or bilateral swelling 
and pain of the parotid gland, and sometimes fever, are the main symptoms, even 
though the overall condition remains good (Saarinen et al. 2013). A male 
predominance has been described, although females are affected more after 
puberty (Kolho et al. 2005, Wang et al. 2009). 
Characteristic endoscopic findings of JRP include pale, atrophic ductal 
mucosa and intraductal debris, and there are also sometimes strictures, stenosis, 
and kinks (Shacham et al. 2009). Diffuse microcalcification throughout the 
parotid glands can often be seen in radiographic imaging. Even in patients with 
unilateral symptoms, bilateral gland disease on imaging is often demonstrated 
(Rosbe et al. 2015). Since JRP usually resolves in puberty, symptomatic treatment 
with NSAIDs, milking, sialogues, and watchful waiting have replaced the other 
invasive treatment methods. The role of antibiotics remains controversial. In 
2004, Nahlieli et al. (2014b) first reported the results of the endoscopic treatment 
of JRP, and sialendoscopy has nowadays been used as a treatment option for JRP. 
2.4.3 Sjögren’s syndrome 
SS is a systemic autoimmune disease characterized by lymphocytic infiltration 
and chronic inflammation of the exocrine glands, mainly the lacrimal and salivary 
glands, and is often accompanied by extraglandular manifestations (Fox 2005). 
SS has a strong female propensity, and the age of onset is usually from four to six 
decades. Most individuals present with xerophthalmia and xerostomia, and about 
one-third have chronic salivary gland swelling (Baldini et al. 2014). The parotid 
gland is the most frequently affected, and the bilateral manifestation is not rare. 
The most common findings in sialendoscopy are a pale, avascular ductal wall, 
mucus plugs, and strictures (Shacham et al. 2011, De Luca et al. 2015, Jager et al. 
2016). Patients have an increased risk of lymphoma, and in case of persistent 
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salivary gland swelling, ultrasound (US) or magnetic resonance imaging (MRI) 
with fine needle biopsy should be considered (Zenone 2012). Usually, dry mouth 
and eyes are treated with local hydrating and lubricating substances. Recurrent 
swelling of the salivary glands is treated with NSAIDs and short-term 
glucocorticoid therapy in selected cases. Systemic glucocorticoids and 
immunosuppressant medicines are used to treat extraglandular manifestations 
(Saraux et al. 2016).  
2.4.4 Chronic sclerosing sialadenitis 
Chronic sclerosing sialadenitis (CSS) is a chronic inflammatory disorder that 
causes salivary gland enlargement. CSS was initially described by Kuttner in 1896 
with the presence of firm, painless, and persistent salivary gland swelling 
commonly affecting the submandibular gland(s) (Geyer et al. 2010). Bilateral, 
painless parotid, submandibular, and lacrimal gland enlargement was historically 
termed as Mikulicz’s disease. In the recent definition, Kuttner’s tumor and 
Mikulicz’s disease are now classified as subcategories of IgG4-related sialadenitis, 
which belong to the larger group of IgG4-RD (Yamamoto et al. 2006, Geyer et al. 
2010). However, not all CSS is related to IgG4. Especially in the Finnish 
population, the rate of IgG4-related sialadenitis is low (Peuraharju et al., 
unpublished data). IgG4-related sialadenitis presents in middle-aged or older 
patients and has an equal gender distribution (Mulholland et al. 2015, Hong et al. 
2017). Orbital manifestations and cervical lymphadenopathy are frequent 
coexisting conditions in the head and neck region, but almost any organ can be 
involved (Mulholland et al. 2015). It is important to discriminate IgG4-related 
sialadenitis from other diseases such as lymphoma, epithelial malignancies, and 
other inflammatory processes since a good response to steroid treatment has been 
described (Yamamoto et al. 2006, Mulholland et al. 2015).  
2.4.5 Treatment of chronic sialadenitis 
The treatment of chronic sialadenitis consists of revealing the symptoms and 
preventing recurrences. The conservative treatments with sialagogues, hydration, 
gland massage, mouth rinses, and NSAIDs are used to stimulate saliva secretion 
and to maintain good oral hygiene in order to reduce the risk of ascending 
infections. Antibiotics should be used in case of acute infection (Zou et al. 1992, 
Motamed et al. 2003). This might be sufficient, especially in mild cases, and some 
patients have a spontaneous improvement of symptoms with symptomatic 
treatment alone (Watkin & Hobsley 1986).  
Different medicines like hyaluronidase, iodized oil, antibiotics, and steroids 
have been injected intraductally to treat chronic sialadenitis. Injecting sclerosing 
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agents such as methyl violet or tetracycline into the parotid duct has been 
reported to induce widespread fibrosis, atrophy, and glandular destruction with a 
resolution of symptoms (Zou et al. 1992, Bowling et al. 1994, Wang et al. 1998). 
Good results have been described with an intraductal installation of penicillin, but 
equally good results were reached in a control group with saline instillation, 
indicating that irrigation itself might be the most important factor, not the 
antimicrobial effect of the penicillin (Antoniades et al. 2004). It has been 
suggested that lavage removes mucus plugs and other inflammatory products, 
eliminating the local source of infection, and dilates the duct, breaking the vicious 
cycle of decreased secretion, stasis, and inflammation (Baurmash 2004). 
Few studies and case reports have described the use of botulinum toxin 
injections in the treatment of chronic sialadenitis (Ellies et al. 2004, Capaccio et 
al. 2008), Stensen’s duct stenosis (Kruegel et al. 2010, Trapeau et al. 2017), and 
SS (Daniel & Diamond 2011, O'Neil et al. 2016) with good results. A botulinum 
toxin injection reduces the secretory capacity of the gland and alleviates the 
obstructive symptoms. However, repeated injections at regular intervals are 
needed as the symptoms usually recur (Lovato et al. 2017). 
Parotid duct ligation has been described as a treatment method of chronic 
parotitis. This is thought to induce pressure atrophy and necrosis of the acini, 
leading to symptom improvement. However, the studies include only a limited 
number of patients, and the results have been controversial, with high a failure 
rate of 50% or more (Nichols 1977, Motamed et al. 2003, Baurmash 2004). 
In tympanic neurectomy, the parasympathetic nerve supply to the parotid 
gland is interrupted by dissecting the parasympathetic fibers at the tympanic 
plexus via a tympanic approach. This is theorized to result in atrophy of the 
parotid gland by reducing the stimulus for salivary production and secretion 
(Mandour et al. 1977). In a retrospective study of 49 patients with chronic 
parotitis treated by tympanic neurectomy, a total or partial resolution of 
symptoms was reported in 82% of patients (Vasama 2000). However, the chorda 
tympani nerve carries some parasympathetic fibers to the parotid glands as well, 
which might explain the variable results (Perera et al. 2000).  
Sialendoscopy has proven to be a promising treatment option for chronic 
sialadenitis, with the possibility to dilate strictures, flush the mucus plugs, and 
administer medicines intraductally. This technique is discussed in more detail 
later. 
Sialadenectomy is an efficient treatment method for chronic sialadenitis but, 
in relation to complications, it should be considered only when other less invasive 
procedures fail. Controversy still exists as to the extent of the parenchymal 
resection required in parotidectomy and whether to ligate the duct (Nouraei et al. 
2007, Patel et al. 2007, Sharma 2013). 
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2.5 Noninflammatory diseases of the salivary glands 
Benign noninflammatory diseases of salivary glands include, e.g., salivary gland 
tumors, cysts, sialadenosis, and radiation or radioiodine (RAI)-induced 
sialadenitis. Sialendoscopy, so far, has no indication in the treatment of tumors, 
cysts, or sialadenosis, but sialadenosis might occasionally be confused with 
chronic sialadenitis. Little experience exists in the treatment of RAI-induced 
sialadenitis with sialendoscopy with promising results (Cung et al. 2017). 
2.5.1 Sialadenosis 
Sialadenosis, also known as sialosis, is an asymptomatic non-inflammatory 
condition characterized by the bilateral enlargement of the salivary glands, most 
commonly involving the parotid glands. It has a multifactorial etiology and is 
most commonly related to alcoholism, diabetes mellitus, endocrinopathy, chronic 
liver disease, bulimia, hyperlipidemia, obesity, or malnutrition. Also, the use of 
certain medicines, mainly antihypertensives or anticholinergic drugs, may induce 
sialadenosis (Scully et al. 2008, Guggenheimer et al. 2009). Peripheral autonomic 
neuropathy is thought to be the unifying feature. The diagnosis is based on the 
patient’s history, US, or MRI to exclude other pathologies, and biopsy in unclear 
cases (Scully et al. 2008). 
2.5.2 Radioiodine-induced sialadenitis 
RAI therapy has been commonly used after total thyroidectomy for patients with 
papillary and follicular thyroid cancer. One of the most frequent complications of 
RAI therapy is salivary gland dysfunction with recurrent swelling and pain in the 
affected glands, and xerostomia (Lee et al. 2015, Moreddu et al. 2017). The 
salivary injury is related to the ability of the salivary glands to concentrate ¹³¹I. 
Serous acini have shown increased uptake of ¹³¹I compared to mucinous acini, 
resulting in an over-representation of parotid gland involvement (Mandel & 
Mandel 2003). RAI-induced sialadenitis can have a significant reduction on 
patients’ quality of life (QoL) (Dingle et al. 2013), and the conservative treatment 
with NSAIDs, hydration, gland massage, sialogues, and steroids is not sufficient 
for a significant portion of patients. Treatment of RAI-induced sialadenitis with 
sialendoscopy is discussed later in more detail. 
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2.6 Radiological imaging of the salivary glands 
Different imaging modalities are used in the diagnosis of salivary gland diseases. 
The US is a cheap, noninvasive, and tolerable but operator-dependent method 
widely used as the first imaging tool. It can detect tumors, local and diffuse 
lesions, dilated ducts, intraglandular microcalcification, and stones (Abdel Razek 
& Mukherji 2017).  
Studies comprising the US as a diagnostic tool for sialolithiasis have 
demonstrated sensitivity and specificity between 65–95% and 80–95%, 
respectively (Terraz et al. 2013, Patel et al. 2014, Schwarz et al. 2015b, Thomas et 
al. 2017, Goncalves et al. 2018). False-negative findings are usually associated 
with calculi with a diameter of less than three millimeters, soft consistency, and 
located in the distal duct. False-positive findings are mainly caused by ductal 
stenosis, scars, and extraductal calcification (Terraz et al. 2013, Goncalves et al. 
2018). Larson et al. (2017) reported in a prospective study that surgeon-
performed US is an accurate way to confirm or rule out sialolithiasis as well as to 
diagnose but not necessarily rule out salivary duct stenosis and estimate 
outcomes. Oral application of ascorbic acid seems to improve visualization of the 
salivary duct in cases of obstruction (Bozzato et al. 2009).  
Other imaging modalities to detect salivary gland pathologies are sialography, 
standard computed tomography (CT), or cone beam computed tomography 
(CBCT), MRI, and magnetic resonance (MR) sialography. Because of the excellent 
delineation of the ductal system, sialography has been considered the gold 
standard for assessing ductal pathology, but related to new imaging techniques 
and the limitations of sialography, such as ionizing radiation, the need for 
contrast media, and pain and invasiveness related to the procedure, its role has 
decreased (Zenk et al. 2009).  
CT or CBCT are particularly useful if there is suspicion of a sialolith with a 
sensitivity of approximately 80–98% and a specificity of 90%, but the patient is 
exposed to the radiation (Schwarz et al. 2015, Thomas et al. 2017). MR 
sialography has shown to be an excellent technique for visualizing the ductal 
system up to the tertiary branches and the parenchymal tissue detecting sialoliths, 
strictures, and stenosis, as well as changes related to chronic sialadenitis 
(Kalinowski et al. 2002, Ren et al. 2015). It is non-invasive, safe, and does not 
require a contrast medium, but it is dependent on salivary flow.  
The scintigraphy technique uses Technetium-99m-pertechnetate and is 
applied as an objective technique to assess salivary gland function as it measures 
the degree of radioisotope uptake and excretion, but due to its rarity and 
expenses, it is used mostly in research and has less relevance in the clinical routine 
(Makdissi et al. 2004, Su et al. 2009). 
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2.7 Sialendoscopy 
Sialendoscopy was developed in Europe to meet the demand for a less invasive 
method to treat salivary obstruction. Sialendoscopy allows the endoscopic 
exploration of the salivary ducts up to the level of secondary and even tertiary 
branches and offers an opportunity to treat salivary duct obstruction (Marchal et 
al. 2000, Nahlieli & Baruchin 2000). The studies that have evaluated the 
diagnostic and therapeutic outcomes of sialendoscopy indicate that it is effective 
and safe in the treatment of obstructive sialadenitis (Marchal et al. 2002, Nahlieli 
& Baruchin 2000, Koch et al. 2012a), and it seems to be efficacious in the 
treatment of inflammatory sialadenitis and sialodochitis as well (Vashishta & 
Gillespie 2013, Ramakrishna et al. 2015). Due to the spread of sialendoscopy, 
there is less need for sialadenectomies. In a nationwide review of data from 
Denmark, there was a 26% reduction of gland excisions performed because of 
benign salivary gland disorders after the introduction of sialendoscopy when 
compared to the 5 years priory (Rasmussen et al. 2016). The only relative 
contraindications for sialendoscopy are complete distal obliteration of the duct 
and the restricted opening of the mouth, as the introduction of the endoscope may 
not be possible, and acute suppurative sialadenitis, as visibility might be poor, 
and there is an increased risk for ductal perforation (Nahlieli et al. 2006a).  
2.7.1 History of sialendoscopy  
The first reported attempts to visualize the salivary duct were performed in the 
early 1990s. Koningsberger et al. (1990) and Gundlach et al. (1990) used a flexible 
endoscope combined with intracorporeal laser lithotripsy for the fragmentation 
of calculi in the salivary glands. In 1991, Katz (1991) introduced a flexible mini-
endoscope with the intent to diagnose diseases of the ductal system of the major 
salivary glands and to remove salivary stones with a Dormia basket in a blind 
technique. In 1994, Arzoz et al. (1996) used a rigid 2.1 mm mini-ureteroscope with 
a working channel of 1 mm and an intracorporeal pneumoballistic lithotriptor or 
laser to fragment and remove the calculi. In the same year, Nahlieli et al. (1994) 
described the use of a rigid mini-arthroscope to diagnose and treat salivary gland 
obstruction, and in 1997, Nahlieli and Baruchin published their three-year 
experience of this new technique. During 1994–1999, Nahlieli and Baruchin 
(2000) treated 236 patients with endoscopy with a success rate of 83% and 
introduced a semi-rigid sialendoscope specially developed for the salivary glands. 
In 2000, Marchal et al. (2000) reported a similar experience and results with 
sialendoscopic techniques. In 2007, Marchal described the combined endoscopic-
external method for the removal of major salivary stones. 
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During the 1990s and 2000s, major advances in optical technologies and the 
development of semi-rigid high-quality endoscopes that are small in diameter 
have established the role of sialendoscopy in a reliable and safe technique for the 
diagnosis and treatment of salivary gland disorders in adults and children 
(Marchal et al. 2002, Nahlieli et al. 2004b, Zenk et al. 2004). 
 
Figure 2  All-in-one sialendoscope and instruments used during sialendoscopy: a knife, 
conic dilators, tweezers, salivary probes, scissors, and criles. Photograph: Antti 
Mäkitie. 
2.7.2 Diagnostic sialendoscopy 
In most cases, diagnostic sialendoscopy can be performed under LA after dilation 
of the papilla. The procedure can be performed either in a sitting or supine 
position. The sialendoscope and the main instruments used during sialendoscopy 
are photographed in Figure 2. Sometimes, mini-papillotomy is necessary to 
introduce the endoscope into a duct (Marchal et al. 2002, Nahlieli et al. 2003). 
While navigating in the duct, intermittent rinsing through the endoscope is used 
to dilate the duct, ensure the visualization, and remove debris. Isotonic saline with 
local anesthetic solution has often been used for this purpose (Marchal et al. 
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2002, Nahlieli et al. 2003). The success rates for diagnostic sialendoscopy have 
varied from 75–100%, usually being around 95–98% with more failures related 
to cases with SS (Chuangqi et al. 2013, Pace et al. 2014, Gallo et al. 2016, 
Karagozoglu et al. 2017). 
Sialendoscopy has proven highly efficient in detecting any ductal changes. 
With sialendoscopy, stenosis and strictures, for example, can be precisely 
assessed with regard to their location, extent, degree of the luminal diameter, 
number, and tissue quality (Koch & Iro 2017), and sialoliths are evaluated by their 
exact location, size, mobility, and adhesion to the ductal wall (Luers et al. 2011). 
Chuangqi et al. (2013) performed sialendoscopy for 561 patients with obstructive 
symptoms and evaluated the pathological features and changes, which were noted 
in 98% of sialendoscopies. Many microanatomical and pathophysiological 
features of the ductal lumen have been noticed with the help of sialendoscopy, 
such as changes in the ductal wall after long-standing inflammation with a matted 
appearance, ecchymosis and paucity of blood vessels, ductal polyps, 
intraparenchymal sialoliths located close to the ductal system, a pelvis-like 
formation in the submandibular hilum and sphincter-like mechanisms in 
Wharton’s duct near the papilla and in Stensen’s ducts more posteriorly (Nahlieli 
& Baruchin 2000, Chuangqi et al. 2013). The sialendoscopic views from the 
normal parotid duct, floating sialolith, and chronic inflammation are presented 
in Figure 3. 
 
Figure 3  Sialendoscopy views of a normal parotid duct, floating sialolith inside the 
submandibular duct, and an avascular ductal wall of the chronic parotitis 
patient. Photographs: Riitta Saarinen.  
Review of the literature 
34 
2.7.3 Interventional sialendoscopy 
2.7.3.1 Treatment of sialoliths 
Endoscopic sialolith removal  
The prognostic factors predicting successful outcomes in sialendoscopic stone 
removal are small size, good mobility, round or oval shape, distal location, and 
shorter duration of symptoms (Luers et al. 2011, Luers et al. 2012a). Stones not 
larger than 4–5 mm can be retrieved using baskets, microdrills, graspers, or micro 
forceps with a success rate of over 80% (Nahlieli et al. 2003, Nahlieli et al. 2006a, 
Walvekar et al. 2009, Zenk et al. 2012), while Luers et al. (2011) observed that the 
success rate drops to 20% in stones exceeding 5 mm, and Marchal et al. (2001a) 
noticed that only 35% of sialoliths larger than 3 mm were able to be removed 
endoscopically without fragmentation. In a study of 942 sialolithiasis patients 
treated with several different methods, Zenk et al. (2012) observed that the 
longest mean diameter of a sialolith that can be removed by sialendoscopy alone 
is 4.2 mm in the parotid and 4.9 mm in the submandibular gland, confirming the 
size limit of 3–5 mm given in the algorithms for successful endoscopic stone 
removal (Marchal &  Dulguerov 2003, Koch et al. 2009). However, mobility of the 
stone seems to be the most important factor in predicting success in endoscopic 
sialolith removal. In a study of 49 sialolith patients, the mobile stones were able 
to be removed endoscopically in 92% of the cases (Luers et al. 2011). Iro et al. 
(2009) reported a successful basket or mirco forceps retrieval rate of 92% among 
the 1522 patients with mobile sialoliths under 5 mm in diameter.  
In the majority of cases, prior fragmentation or transductal surgery is 
necessary due to the sialolith’s size and adherence (Zenk et al. 2012). Various 
methods of intraductal fragmentation have been developed for stones that are 
achievable endoscopically, including mechanical fragmentation, using a micro 
drill or micro forceps (Nahlieli et al. 2003), lasers (Durbec et al. 2012, Phillips & 
Withrow 2014), and electrohydraulic (Marchal et al. 2002, Nakayama et al. 2007) 
or pneumatic lithotripsy (Koch et al. 2019). Recent results with intraductal laser 
lithotripsy have success rates of over 80–90%, and the holmium laser has been 
the most frequently used (Durbec et al. 2012, Phillips & Withrow 2014, Sionis et 
al. 2014). However, the laser should be used only in clear vision, and the surgeon 
should be aware of potential dangers such as absorption in the surrounding tissue 
and heat generated from the fragmentation since complications have been 
described after laser fragmentation in the form of serious trauma with total 
obliteration of the duct and ductal perforation (Durbec et al. 2012, Sahin-Yilmaz 
&  Oysu 2015). The preliminary experiences of intraductal pneumatic lithotripsy 
have been promising, with success rates of 88–98% (Serbetci et al. 2017, Koch et 
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al. 2019). Koch et al. (2019) performed a checkup endoscopy on the first and 
second days to remove residual fragments and fibrinous plaques, and at the 4- 
and 8-week checkups, they found no severe scar formation or stenosis. 
 
Figure 4 Basket removal of the sialolith from the submandibular duct. Photograph: Riitta 
Saarinen.  
Sialendoscopy-assisted transoral removal of submandibular sialoliths 
Sialendoscopy-assisted transoral stone removal is possible in patients with 
submandibular sialoliths situated in the main duct or hilar region with high 
success rates of 87–95% (Iro et al. 2009, Su et al. 2010, Zenk et al. 2012, Liu et al. 
2013). In this technique, the sialolith is verified with a sialendoscope, and 
afterward, an incision is made in the mucosa. The floor of the mouth is then raised 
with digital pressure from the submandibular region, and a limited incision is 
made in the duct over the stone with the help of the endoscope light (Marchal 
2007, Su et al. 2010, Liu et al. 2013). Prophylactic antibiotics are often used (Liu 
et al. 2013, Schwartz et al. 2015a), and many authors favor the use of stents left in 
place for varying times (Marchal 2007, Su et al. 2010, Liu et al. 2013, Schwartz et 
al. 2015a). This approach is particularly valuable in immobile, non-palpable 
stones (Fabie et al. 2019). Other advantages are the possibility of identifying or 
ensuring the exact location of the stone and exploring the remaining duct against 
residual stones or strictures.  
Sialendoscopy-assisted transoral removal of parotid sialoliths 
Sialendoscopy-assisted transoral stone removal has been used for impacted 
parotid stones located distally. In this technique, a semicircular mucosal incision 
is made approximately 1 cm anterior to the papilla, and after submucosal 
dissection, the duct is exposed and incised longitudinally over the stone. A 
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sialendoscopic control of the whole duct tree is then performed and the duct is 
closed with stitches. Stents are often used to prevent scarring (Overton et al. 2012, 
Zheng et al. 2015, Foletti et al. 2016, Ye et al. 2017). In a retrospective study of 22 
patients with parotid sialoliths, Foletti et al. (2016) concluded that this technique 
is recommendable for the anterior-third parotid duct sialoliths located in front of 
the anterior edge of the masseter with a success rate of 88%, but there are 
limitations for more posterior stones with success rates of 63% and 25% in the 
removal of the middle-third and posterior-third sialoliths, respectively.  
Sialendoscopy-assisted transcutaneous removal of parotid sialoliths  
Sialendoscopy-assisted transcutaneous removal of parotid stones is used if 
endoscopic removal is not possible due to large size, adherence, or intraglandular 
location of the stone. The sialendoscope is used to localize the stone, and the stone 
is removed externally using a modified Blair incision (Carroll et al. 2013, Ong et 
al. 2017), a modified facelift incision (Marchal 2007, Capaccio et al. 2014), or an 
incision directly over the stone (Nahlieli et al. 2002, Rotnagl et al. 2016). Facial 
nerve monitoring is recommended (Koch et al. 2013, Kopec et al. 2013a, 
Konstantinidis et al. 2015, Ong et al. 2017). When the sialolith has been removed, 
the duct is visualized for further stones, after which it is repaired and the parotid 
fascia is closed. Many studies describe the use of stents for the reconstruction of 
Stensen’s duct (Nahlieli et al. 2002, Koch et al. 2013, Klein & Ardekian 2014, 
Konstantinidis et al. 2015, Rotnagl et al. 2016). Prophylactic antibiotics are used 
often (Nahlieli et al. 2002, Karavidas et al. 2010, Ong et al. 2017), and a few 
studies report the administration of perioperative steroids to prevent swelling and 
decrease the risk of ductal stenosis (Carroll et al. 2013, Rotnagl et al. 2016, Ong et 
al. 2017). The review of published articles on the focus of sialendoscopy-assisted 
transcutaneus removal of parotid sialoliths in Table 1 shows success rates between 
75–100% for this technique. The high-resolution US has also been used to identify 
the exact location of the sialolith alone or in combination with the endoscope and 
is especially useful in cases where navigation with the endoscope is impossible 
(Nahlieli et al. 2002, Karavidas et al. 2010, Carroll et al. 2013). 
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2.7.3.2 Treatment of strictures and stenosis 
Classification of stenosis 
Koch & Iro (2017) analyzed the sialendoscopy findings of 550 symptomatic 
stenoses of Stensen’s duct and classified each in relation to tissue characteristics 
and appearance: type 1 stenosis (8.9%) was characterized by inflammatory 
changes, type 2 (19.5%) was associated with circular or weblike changes and 
ductal dilatation, and type 3 (71.6%) was characterized by fibrotic reactions with 
diffuse involvement of the duct. They also used a sialendoscope to grade the 
narrowest part of the stenosis from I (passable with 1.1 mm endoscope) to IV 
(complete stenosis) (Koch & Iro 2017). Stenosis can also be classified based on its 
location. Most stenoses are found in the middle or distal regions of the duct, while 
only 8–18% of Stensen’s duct stenoses and approximately 18% of Wharton’s duct 
stenoses are located in the proximal segment (Koch et al. 2009, Koch et al. 2012b, 
Kopec et al. 2013b, Koch & Iro 2017). 
Sialendoscopy-assisted treatment of duct stenosis  
The location, grade, and tissue characteristics are the most important factors 
when treating duct stenosis. In a series of 153 symptomatic stenoses of the 
submandibular duct, transoral surgery with papillotomy or extended ductal 
incision and marsupialization were used in 58% of cases, most often in distal 
stenosis. Endoscopic treatment with dilatation of the stricture with a basket or 
micro drill were used for 27% and cortisone irrigation alone in 12%. Repeated 
intraductal cortisone instillation was carried out for endoscopically treated 
patients after the procedure (Koch et al. 2012b). Kopec et al. (2013b) used a 
micro-instrument, such as the micro burr, and Nahlieli et al. (2001) mainly used 
balloons to dilate the strictures of Wharton’s and Stensen’s ducts. Ardekian et al. 
(2010) treated 87 parotid duct stenoses with hydrostatic pressure and the 
sialendoscope itself or more advanced cases with sialo-balloons or forced 
manipulation with microdrills. Stents have been actively used, and a significant 
improvement of symptoms has occurred in approximately 80% of cases (Nahlieli 
et al. 2001, Ardekian et al. 2010, Kopec et al. 2013b). 
Koch et al. (2012a) presented a study of 93 patients with 111 stenoses in 
Stensen’s duct. Endoscopic dilatation of stenosis with a basket or micro drill was 
used successfully in 59% of cases, hydrostatic pressure and cortisone irrigation as 
the only treatment in 22%, and transductal surgery with papillotomy, distal ductal 
incision, or ductal resection with reinsertion and stent placement in 8.6%. 
Steroids seemed beneficial in cases of inflammatory stenosis with ductal edema 
and hyperemia. The gland preservation rate was 96%. In 2014, Koch et al. (2014) 
published long-term follow-up results from 82 out of 93 patients with Stensen’s 
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duct stenosis who were treated during 2001–2006, as described previously. After 
an average follow-up of 98 months, 50% of patients were symptom-free, while 
50% of patients continued to have low-grade swelling and 20% continued to have 
pain.  
The sialendoscopy-assisted transcutaneous treatment of difficult Stensen’s 
duct stenosis with vein patch or replacement of the duct by vein interposition has 
also been described (Koch et al. 2013). 
2.7.3.3 Treatment of chronic sialadenitis 
During the past decade, promising results have been reported in the treatment of 
chronic sialadenitis, including JRP, chronic recurrent parotitis, autoimmune-
related sialadenitis, and RAI-induced sialadenitis (Nahlieli et al. 2004a, Shacham 
et al. 2009, Shacham et al. 2011, De Luca et al. 2014, Bhayani et al. 2015, Delagnes 
et al. 2017a, Jager et al. 2016, Capaccio et al. 2017). The therapeutic options for 
sialendoscopy are the irrigation and removal of mucus plugs and debris, 
dilatation of stenosis and strictures, and infusion of medicines to reduce the 
inflammation. Intraductal steroids have often been used in a lavage solution or as 
a dosage after sialendoscopy, but other drugs such as iodized oil, antibiotics, and 
chymotrypsin have also been tried therapeutically (Yu et al. 2008, Vashishta 
2013, Sun et al. 2017). Delagnes et al. (2017a) observed that concurrent use of 
triamcinolone irrigation with sialendoscopy is associated with better symptom 
resolution in patients with non-sialolith sialadenitis, but in multivariate analysis, 
this finding was not statistically significant. Capaccio et al. (2017) concluded in a 
prospective, randomized study that a combination of interventional 
sialendoscopy followed by repeated ductal steroid irrigations at the outpatient 
clinic produced a better outcome than sialendoscopy alone in the treatment of 
recurrent sine causa sialadenitis. Recently, Sun et al. (2017) discovered that 
sialendoscopy with irrigation of chymotrypsin combined with gentamicin was a 
more effective treatment for chronic non-stone–related obstructive parotitis than 
sialendoscopy with gentamicin alone. 
Treatment of juvenile recurrent parotitis  
Many series have reported good results in the treatment of JRP with 
sialendoscopy, but the population sizes are small and the follow-up periods rather 
short. In a meta-analysis of 120 patients with JRP, the weighted pooled 
proportion of success rates for no further episodes after sialendoscopy in patients 
was 73%. The follow-up times ranged from 0 to 36 months (Ramakrishna et al. 
2015). However, despite the potential benefits of sialendoscopy, its role remains 
controversial in the treatment of JRP. Schneider et al. (2014) compared patients 
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treated with sialendoscopy with cortisone irrigation to those treated with oral 
antibiotic therapy alone and found equal therapeutic outcomes. Rosbe et al. 
(2015) compared the effectiveness and costs of sialendoscopy to conservative 
therapy and observed similar outcomes with higher costs related to 
sialendoscopy. Roby et al. (2015) treated JRP patients with intraductal steroid 
infusion alone and found an improved quality of life in 75% of patients, which is 
similar to what has been reported after sialendoscopy. A retrospective setup and 
the absence of randomization and a control group are the limitations in these 
studies. 
Treatment of Sjögren ’s syndrome–related sialadenitis  
Sialendoscopy seems to reduce the symptoms of SS-related sialadenitis. In 
retrospective studies, an improvement of symptoms has been achieved in 85–
100% of patients after a mean follow-up of 6–11 months (Shacham et al. 2011, De 
Luca et al. 2015). In prospective studies, good results with a reduction of 
glandular swelling and pain as well as xerostomia have been found after 
sialendoscopy. Also, marks of increased salivary flow have been noticed (Jager et 
al. 2016, Capaccio et al. 2017, Karagozoglu et al. 2018). However, it should be 
considered that improvement in salivary flow is possible only if saliva-producing 
acinar cells are present, so the stage of the disease is expected to have an 
important impact on the success (Karagozoglu et al. 2018). 
Treatment of radioiodine-induced sialadenitis 
Although limited to a small case series, sialendoscopy seems to be effective in the 
treatment of RAI-induced sialadenitis. Clinical improvement has been observed 
in 75–100% of patients treated with sialendoscopy (Nahlieli & Nazarian 2006b, 
Bomeli et al. 2009, Prendes et al. 2012, De Luca et al. 2014). In a prospective study 
of 26 RAI sialadenitis patients, Bhayani et al. (2015) discovered a complete or 
partial resolution of symptoms in 92% of patients, while 77% had complete or 
partial resolution of their xerostomia symptoms. Also, significant improvement 
in saliva production was seen at the 6-month follow-up. Wu et al. (2015a) found 
an improved uptake and excretion by salivary gland scintigraphy in 79% of 19 
glands. Contrarily, Kim et al. (2016) observed that no significant change was 
found in xerostomia-related symptoms, salivary flow rates, or scintigraphy 
functional results in 10 patient series. 
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Table 2. Indications for sialendoscopy and existing evidence of literature 
Disorder Indication for 
sialendoscopy 
Conservative 
treatment 
Evidence of 
sialendoscopy 
Related studies 
Obstructive 
sialadenitis 
Recurrent swelling 
with tenderness of 
the affected gland 
(might be related to 
eating), detected 
sialolith, repeated 
bacterial infections 
related to 
mechanical 
obstruction  
Symptoms 
rarely/ 
occasionally, 
random 
bacterial 
infections  
Good evidence, 
several studies 
Strychowsky et al. 2012 
(systematic review and 
meta-analysis) 
Atienza & Lopez-Cedrun 
2015 (systematic review 
and meta-analysis) 
Sialoliths All parotid sialoliths, 
all non-palpable 
submandibular 
sialoliths, 
hilar/intraglandular 
sialoliths of the 
submandibular 
gland 
Palpable 
sialolith in the 
main duct of 
the 
submandibular 
gland -> 
transoral 
removal 
Good evidence, 
several studies 
Ryan et al. 2019 
(prospective follow-up 
study) 
Roland et al. 2017 
(systematic review and 
meta-analysis) 
Strictures Suspicion of 
stricture/stenosis, 
obstructive 
symptoms of 
unclear origin 
 Good evidence; 
several, mainly 
retrospective 
studies 
Plonowska et al. 2019 
(prospective follow-up 
study) 
Erkul et al. 2016 
(systematic review) 
Ardekian et al. 2010 
(retrospective study) 
Nahlieli et al. 2001 
(retrospective study) 
Chronic 
recurrent 
parotitis 
Repeated or 
persistent swelling 
and tenderness of 
the affected gland, 
moderate or severe 
symptoms  
Mild or 
moderate 
symptoms, 
symptoms 
occasionally 
Moderate 
evidence; mainly 
retrospective case 
series with 
submandibular 
patients also 
included 
Capaccio et al. 2017 
(prospective study) 
Sun et al. 2017 
(prospective study) 
Wu et al. 2015 
(retrospective study) 
Vashishta & Gillespie 
2013 (retrospective case 
series) 
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JRP Severe symptoms, 
diagnostic in unclear 
cases  
Majority of 
cases with 
tolerable 
symptoms 
Evidence 
controversial; 
small case series,  
lack of 
prospective, 
randomized 
controlled studies  
Garavello et al. 2018 
(systematic review) 
Ramakrishna et al. 2015 
(systematic review and 
meta-analysis) 
Rosbe et al. 2015 
(retrospective 
observational study) 
Schneider et al. 2014 
(retrospective study) 
Sjögren’s 
syndrome  
Repeated or 
persistent swelling 
and tenderness of 
the affected gland, 
moderate or severe 
symptoms 
Mild or 
moderate 
symptoms, 
xerostomia 
Moderate 
evidence; 
preliminary 
evidence that 
sialendoscopy can 
also improve the 
symptoms of 
xerostomia, small 
sample sizes 
Karagozoglu et al. 2018 
(prospective, randomized 
controlled study) 
Capaccio et al. 2017 
(prospective study) 
Jager et al. 2016 
(prospective, randomized 
controlled study) 
RAI-
induced 
sialadenitis 
Repeated or 
persistent swelling 
and tenderness of 
the affected gland, 
moderate or severe 
symptoms 
Mild or 
moderate 
symptoms, 
xerostomia 
Moderate 
evidence; 
controversial 
evidence of 
treatment of 
xerostomia with 
sialendoscopy; 
small case series, 
lack of 
prospective, 
randomized 
controlled studies 
Erkul et al. 2016 
(systematic review) 
 
  
 43 
2.7.4 Complications 
Diagnostic and interventional sialendoscopy have proven to be safe procedures 
but not free of complications. Complication rates between 1–30% have been 
reported depending on the definition, study population, and size (Marchal et al. 
2002, Nahlieli et al. 2003, Koch et al. 2005, Nahlieli et al. 2006a, Papadaki et al. 
2008, Walvekar et al. 2008, Rasmussen et al. 2012, Gallo et al. 2016, Karagozoglu 
et al. 2017). The most prevalent complications seem to be ductal perforations 
(Marchal et al. 2002, Gallo et al. 2016), postoperative strictures (Nahlieli et al. 
2006a), and infections (Rasmussen et al. 2012). Temporary lingual nerve 
paresthesia, wire basket blockages, ranula formation, and hemorrhage have also 
been described in the literature after interventional procedures (Nahlieli et al. 
2006a, Capaccio et al. 2016, Gallo et al. 2016). Complications confronted after 
endoscopy-assisted transcutaneous sialolith removal are presented in Table 1. 
Nahlieli (2015) analyzed the complications of 526 patients treated with 
interventional sialendoscopy due to sialolithiasis. The complications were 
confronted in 3.2% of cases in the forms of stricture (1.7%), ranula (1.3%), and 
lingual nerve paresthesia (0.6%). In an Italian multicenter study of 1309 
diagnostic and interventional sialendoscopies, the complications were observed 
in 5.4% of procedures, most often as ductal perforation (Gallo et al. 2016). The 
main limitation of these studies is their retrospective design, which might 
underestimate the complication rates.  
Postoperative glandular swelling is a normal reaction after sialendoscopy due 
to ductal irrigation and fluid retention, and it usually resolves after a few hours 
(Nahlieli et al. 2003). Excessive swelling of the affected gland and submucosal 
surroundings after sialendoscopy is usually due to perforation of the duct and 
excessive irrigation. Such swelling usually resolves in approximately 24 hours. 
However, this complication is important to notice because swelling can, in some 
cases, cause an airway compromise (Papadaki et al. 2008, Martins-Carvalho et al. 
2010). Other major complications that have been described include avulsion of 
the main duct leading to salvage superficial parotidectomy (Walvekar et al. 2008). 
2.7.5 Cost-effectiveness of sialendoscopy 
Society often invests in health care without definite knowledge of the health 
benefit reached. This happens especially when new treatments and technologies 
are developed. Only a few studies have evaluated the costs and cost-effectiveness 
of sialendoscopy and sialendoscopy-assisted surgery. Felton et al. (2012) 
summarized the coding prices of the UK Trust for salivary gland procedures in 
2011. The prices for adults were £612 for sialendoscopy ± stone removal, £552 for 
sialendoscopy ± duct dilatation, and £1962 for submandibular gland excision or 
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superficial parotidectomy, which shows that sialendoscopy is much cheaper than 
gland excision. Shashinder et al. (2011) calculated that the average cost of 
transoral sialolith removal was approximately £197, concluding that this 
procedure is more cost-effective than other alternative options such as 
sialendoscopy or gland resection. Rosbe et al. (2015) found that the average costs 
of care of JRP treated with sialendoscopy ($31,338 per patient) were much higher 
than those treated conservatively ($698 per patient), but the outcomes were the 
same. However, this study was not randomized, and the sialendoscopy patients 
were selected for the operation because their more frequent symptoms making 
the comparison difficult. Ong et al. (2017) showed that the transfacial 
sialendoscopy-assisted removal of parotid stones ($22,482) was less expensive 
and faster compared to the traditional parotidectomy ($30,546) performed 
because of chronic sialadenitis minimizing the time needed for surgery and 
maximazing hospital resources, and Kowalczyk et al. (2018) showed that the 
upfront sialendoscopy is more cost-effective treatment for RAI-induced 
sialadenitis than medical management utilizing US when the willingness-to-pay 
threshold is $50,000. Lately, Coniglio et al. (2019) compared the costs of 
sialendoscopy performed at the office under LA to similar procedures performed 
in the operating room under GA and noticed a significant reduction in time and 
financial burden for the patients with the in-office procedure, although the 
outcomes were similar. However, most of these studies were retrospective. Also, 
the different build-up of hospital costs in different countries makes comparing 
the results difficult. 
2.8 Assessing health-related quality of life (HRQoL) 
No single definition of QoL exists. According to The World Health Organization 
(WHO), QoL is a broad but complex concept that is affected by a person’s physical 
health, psychological state, personal value and beliefs, social relationships, 
environment, and level of independence. The WHO defines QoL as “an 
individual’s perception of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, 
standards and concerns” (WHOQOL Group 1994). HRQoL can be used to 
describe the effects of a disease, disability, or disorder on QoL and the effect of 
treatment or clinical intervention on health and general well-being. HRQoL is a 
multidimensional concept that encompasses physical, mental, and social aspects 
and is affected by the general condition of the individual, other health problems 
and sicknesses experienced, and the phase of life. HRQoL is a subjective matter, 
and the individuals themselves should assess it (Guyatt et al. 1993). 
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The severity and frequency of the disease can be easily measured, but when 
assessing HRQoL, specific instruments are needed to evaluate the changes over 
time and under altering living circumstances. Two kinds of HRQoL instruments 
exist: generic and disease-specific ones. The disease-specific instruments are 
more sensitive to the effects of a specific disease and intervention in health status, 
but they are not suited to compare treatment results across various diseases. 
Generic instruments allow the comparison of diverse patient groups with 
different underlying disease and clinical interventions to each other and to the 
general population. They can be classified into profile and single-index score 
measures. The profile instrument characterizes the health status from the 
perspective of various physical and emotional dimensions, such as bodily pain, 
general health, vitality, social and mental functioning, etc. The single-index score 
instrument is used to produce a single index score, which is needed to calculate 
the quality-adjusted life-years used to estimate the cost-effectiveness of various 
interventions (Guyatt et al. 1993). The methods differ among different HRQoL 
instruments, and when choosing the instrument, one must consider its validity, 
reliability, sensitivity, and usability (Moock & Kohlmann 2008). 
The Finnish 15-dimensional health-related quality of life (15D HRQoL) 
questionnaire is a standardized and validated, generic, self-administered tool to 
measure HRQoL. It can be used both as a single index score and as a profile of 15 
different dimensions including mobility, vision, hearing, breathing, sleeping, 
eating, speech, excretion, usual activities, mental function, discomfort and 
symptoms, depression, distress, vitality, and sexual activity. A single index score 
on a scale of 0 to 1 is obtained by incorporating the population-based preference 
weights to the dimensions, representing the overall HRQoL (Sintonen 2001). The 
15D can be used to calculate quality-adjusted life-years, and it has been developed 
to measure the cost utility of different treatments or interventions in health care 
(Sintonen 2001). The 15D is shown to be highly reliable and responsive to change, 
and it compares favorably with other similar instruments (Hawthorne et al. 2001, 
Moock & Kohlmann 2008). 
2.8.1 HRQoL after sialendoscopy 
The impact of sialendoscopy on patients’ HRQoL has been little explored. No 
validated disease-specific questionnaire for capturing salivary gland–related QoL 
exists today, and only a few studies have used validated generic surveys. A study 
using the Short-Form-36 Health Survey (SF-36) showed significantly worse 
values in vitality and mental health after sialendoscopy when compared to the 
age- and gender-matched reference group referring to potentially persisting 
symptoms. Patients with daily symptoms suffered more bodily pain and felt more 
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restricted in daily activities than patients with recurrent symptoms. When 
symptoms were chronic and not ingestion-related, physical functioning decreased 
(Kroll et al. 2013). The study lacks a preoperative assessment, so the potential 
benefits of sialendoscopy cannot be estimated. Further, two studies have used the 
Glasgow Benefit Inventory (GBI) survey to assess the improvement of patients’ 
HRQoL after sialendoscopy. A positive effect was noticed in both studies 
comparing well with other common otorhinolaryngological procedures where the 
GBI has been reported (Ianovski et al. 2014, Meier et al. 2015).  
The need for a sensitive tool to assess the salivary gland–related symptoms 
and HRQoL has recently been recognized. Because of the lack of validated 
questionnaires, Gillespie et al. (2015) used a modified Oral Health Impact Profile-
14 (OHIP-14) survey to measure the salivary gland–specific HRQoL after 
sialendoscopy. The overall modified OHIP-14 scores (mean score 7.8, median 
score 2) showed that the level of ongoing impairment was relatively mild. Patients 
with sialoliths had better salivary gland–related QoL compared to patients with 
non-stone etiology. However, this study also lacks a preoperative evaluation.  
In 2015, Aubin-Pouliot et al. (2016b) introduced the Chronic Obstructive 
Sialadenitis Symptoms (COSS) questionnaire to numerically characterize 
sialadenitis-specific symptoms experienced by patients at a given point in time 
and to resolve the impact of these symptoms on daily functions reflecting the 
HRQoL, such as chewing, speaking, and swallowing, as well as sleeping, daily 
activities, and emotional symptoms. This self-administered 20-question survey 
gives a single COSS score from 0–100; a greater COSS score indicates more severe 
symptoms and disease impact. The COSS questionnaire has proven to be a useful 
tool in capturing changes in sialadenitis-specific symptoms after sialendoscopy 
(Aubin-Pouliot et al. 2016a, Delagnes et al. 2017a, Delagnes et al. 2017b), and it 
has shown that sialendoscopy-assisted salivary duct surgery (SASDS) is effective 
in reducing symptoms in both sialolithiasis patients and in patients with chronic 
obstructive sialadenitis without sialolithiasis (Ryan et al. 2019, Plonowska et al. 
2019). However, the validity and reliability of the COSS questionnaire need to be 
assessed in further studies. 
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3 AIMS OF THE STUDY 
The general objectives of this thesis were to study the outcome of the 
sialendoscopic management of sialolithiasis and sialadenitis, to assess HRQoL 
and complications related to the sialendoscopic approach, and to evaluate the 
costs related to the treatment of patients with sialadenitis. 
 
The specific aims were: 
 
1. To study the individual treatment outcome of sialolithiasis, duct 
stenosis/strictures, and chronic sialadenitis/sialodochitis after 
sialendoscopic approach. 
 
2. To assess the patient-reported experience and compliance after a 
sialendoscopy procedure under LA or LAS.  
 
3. To investigate the efficacy of sialendoscopy in the treatment of adult 
chronic recurrent parotitis and to resolve the possible benefit of a single-
dose intraductal steroid injection given concurrently with sialendoscopy. 
 
4. To determine complications related to both diagnostic and interventional 
sialendoscopy.  
 
5. To assess the HRQoL of patients with recurrent sialadenitis and the 
possible effects of sialendoscopy on their HRQoL.  
 
6. To assess the hospital costs related to the treatment of patients with 
recurrent sialadenitis, the sialendoscopy procedure, and the 
complications of sialendoscopy. 
Patients and methods 
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4 PATIENTS AND METHODS 
This dissertation consists of five studies. All were conducted at the Department of 
Otorhinolaryngology – Head and Neck Surgery, HUS, in Helsinki Finland, which 
is a tertiary-care academic teaching hospital covering about 1.6 million 
inhabitants.  
4.1 Patients 
Study I 
All patients who underwent sialendoscopy at the Department of 
Otorhinolaryngology – Head and Neck Surgery, HUS, between January 2011 and 
December 2013 were retrospectively extracted from the hospital’s electronic 
database. A total of 228 patients (61% female; mean age 46 years, range 4–81; 17 
children or adolescents) underwent 266 sialendoscopies and were included in the 
study. There were 18 patients who underwent bilateral sialendoscopy, and 19 
underwent more than one during the study period.  
Study II  
Patients who underwent sialendoscopy at the Department of 
Otorhinolaryngology – Head and Neck Surgery, HUS, between March 2012 and 
December 2013 participated in the study by filling out a questionnaire formulated 
by the authors. All the patients were operated on by one of the two surgeons 
performing the most sialendoscopies in the clinic at that point. Patients operated 
on by other physicians, children under 16 years, patients with insufficient Finnish 
language skills, patients not able to recruit for the study preoperatively, and 
patients who underwent the sialendoscopy under GA were excluded. In all, 89 of 
132 patients answered the questionnaire and were included (56% female; mean 
age 50 years, range 16–81). Seven patients underwent bilateral sialendoscopy.  
Study III 
Fifty-four patients with symptoms of chronic recurrent parotitis not responding 
to conservative treatment were recruited prospectively at the out-patient clinic of 
the Department of Otorhinolaryngology – Head and Neck Surgery, HUS, between 
March 2012 and December 2015. Patient inclusion criteria were at least three 
prolonged (over 24 hours) or ten shorter episodes of parotid swelling with or 
without pain during the previous six months and age over 18 years. The exclusion 
criteria were sialolith(s) detected in preoperative US or MRI or during a 
sialendoscopy procedure and insufficient Finnish or Swedish language skills. A 
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total of 49 patients (67% female; mean age 53 years, range 21–75) were included. 
Five recruited patients were excluded due to spontaneous symptom improvement 
while waiting for the endoscopy. Eight patients underwent bilateral 
sialendoscopy.   
Study IV 
Patients who underwent sialendoscopy at the Department of 
Otorhinolaryngology – Head and Neck Surgery, HUS, between October 2015 and 
December 2016 were prospectively recruited for a complication register study. 
Exclusion criteria were age under 16 years, insufficient Finnish or Swedish 
language skills, and lack of written informed consent due to failure to 
prospectively recruit the patients, or patients’ refusal from the study. Altogether, 
118 of 147 patients (69% female; median age 47 years, range 19–86)   with 140 
sialendoscopies were included in the study. Fifteen patients underwent 
sialendoscopy for multiple glands and seven underwent re-sialendoscopy during 
the study period. 
Study V 
All patients who underwent sialendoscopy at the Department of 
Otorhinolaryngology – Head and Neck Surgery, HUS, between January 2014 and 
May 2016 were extracted from the hospital’s electronic database. In all, 260 
patients (66% female; mean age 46 years, range 4–86) were found, and the direct 
hospital costs of those patients covering the time interval of two years (one year 
prior to sialendoscopy and one year after sialendoscopy) were resolved.   
In addition, questionnaires on HRQoL and use of health care services were 
sent to 188 patients. At baseline, 74 (39%) patients (female 72%; mean age 51  
years, range 15–86), after 6 months 60 patients (32%), and after 12 months 56 
patients (30%) returned the questionnaires. All three 15D HRQoL questionnaires 
were returned by 51 patients (27%). Of these patients, 43 (23%) returned the 
questionnaire concerning the use of primary health care services related to 
salivary gland disease during the preceding three months. Exclusion criteria were 
age under 15 years or insufficient Finnish or Swedish language skills. Additionally, 
some patients were not reached because of changed operation schedules. Twelve 
patients underwent re-sialendoscopy during the study period.  
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4.2 Methods 
4.2.1 Sialendoscopy 
All patients included in the studies underwent sialendoscopy or a sialendoscopy-
assisted interventional procedure according to the same protocols. All-in-one 
sialendoscopes (Karl Storz 11575 A, 11576 and 11573 A) were used. LA, LAS, or GA 
were used based on the patients’ age, co-operation, and expected complexity of 
the procedure. LA was achieved using a 10% lidocaine-hydrochloride spray and 
by infiltration of 1% lidocaine with adrenaline under the papilla. After papilla 
dilatation, 1% lidocaine was administered into the duct. The ductal system was 
then explored under intermittent lavage with an irrigation solution of 1% 
lidocaine and 0.9% sodium chloride at a ratio of 1:4. Debris was rinsed out and 
strictures opened with the help of hydrostatic pressure, the endoscope, a salivary 
duct probe, a micro drill, or a basket if possible. Sialoliths near the papilla of 
Wharton’s duct were removed via papillotomy, and sialoliths further in the duct 
with a Dormia basket, if permitted by the size and mobility of the stone. Large or 
immobile sialoliths were removed by making an incision in the floor of the mouth 
atop the sialolith. For the parotid gland, an endoscopy-assisted transcutaneous 
approach with a local skin incision or modified facelift incision was used. After 
transoral sialolith removal, the wound was left open and no stents or 
sialodochoplasty were used. After endoscopy-assisted transfacial sialolith 
removal, the duct, parotid capsule, and skin were closed carefully without 
stenting. Stents were used only to treat persistent strictures. Prophylactic 
antibiotics (cefuroxime 1.5 g intravenously intraoperatively, or cephalexin orally 
for 5–7 days postoperatively) were used under consideration of the surgeon in 
complicated procedures. Steroid irrigation (1 mL of hydrocortisone, 125 mg/mL) 
was used in patients with signs of chronic inflammation at the end of the 
procedure.  
4.2.2 Medical records 
The medical records of every patient were reviewed and the following information 
registered: patient demographics, characteristics as well as necessary medical 
data, comorbidities, American Society of Anesthesiologists (ASA) Physical Status 
Classification Score, symptoms, symptomatic salivary gland, operated salivary 
gland, performing surgeon, sialendoscopy findings, type of surgical intervention, 
operation time, anesthesia, use of antibiotics and corticosteroids, complications, 
treatment outcome, treatment failure, and further treatments. Patients’ general 
health was assessed using the Charlson Comorbidity Index (CCI) in study IV 
(Charlson et al. 1987).   
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The direct hospital costs were obtained from the Ecomed clinical patient 
administration system (Datawell Ltd, Finland), where all the hospital costs from 
the Hospital District of Helsinki and Uusimaa are routinely stored. The costs 
related to the diagnosis and treatment of the patients’ salivary gland disease 
including imaging and laboratory services, outpatient visits, pathology 
examinations, operations, and inpatient care were calculated. Also, the direct 
hospital costs related to the possible complications of sialendoscopy were 
analyzed (study V).  
The performed sialendoscopies during the time period of interest were 
received from the hospital’s electronic surgical database, which uses the Finnish 
nationwide classification of surgical procedures maintained by The National 
Institute for Health and Welfare and is based on the Nordic Classification of 
Surgical Procedures (NCSP). 
4.2.3 Questionnaires (II, III, V) 
In study II, patients completed a questionnaire in which they rated their 
sensations (level of nervousness before the operation, level of discomfort and pain 
during the operation, and level of pain after the operation) using a scale of none, 
mild, moderate, and major. Patients were also asked if they would agree to a new 
sialendoscopy under LA/LAS later if needed. The questionnaires were filled in 
after the operation. 
In study III, patients filled out a questionnaire in which they estimated the 
frequency of symptoms during the previous three months and marked the most 
suitable option from a scale: symptoms weekly, symptoms 2 to 3 times a month, 
symptoms once a month, symptoms more rarely, and no symptoms. They also 
rated the severity of symptoms during the previous three months with a visual 
analogue scale (VAS; horizontal line of 10 cm; 0 = no symptoms, 10 = the worst 
possible symptoms) by marking the average score on a VAS line. In addition, they 
estimated the course of the symptoms during the previous three months from a 
scale: symptom-free, symptoms decreased significantly, decreased slightly, 
remained unchanged, increased slightly, or increased significantly. The 
questionnaires were completed before the sialendoscopy and three, six, and 
twelve months postoperatively.  
In study V, the generic 15D HRQoL questionnaire was used. The 15D consists 
of 15 dimensions, as introduced in chapter 2.8. In each dimension, the respondent 
chooses one of five levels that best describes their current state of health. The 15D 
constructs a 15-dimensional profile and a single index score between 0 
(equivalent to being dead) to 1 (no problems at any dimension) (Sintonen 2001). 
The minimal clinically important change or difference in the 15D has been 
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estimated to be ± 0.015 (Alanne et al. 2015).  The age- and gender-matched 
representative population was obtained from The National Health 2011 Survey 
(Koskinen et al. 2012).  
Also, the self-made questionnaire about the use of health care services related 
to patients’ salivary gland disorders was posted to the patients in study V. In the 
questionnaire, patients evaluated the number of doctoral visits, nurse’s 
receptions, phone calls, and laboratory services conducted in public or private 
health care, as well as inpatient treatments and the number of sick leave days 
required because of salivary gland disorder during the previous three months. The 
use of services and duration of sick leave were converted into monetary units 
based on the most recent Finnish data on standard unit costs from 2011 
(Kapiainen et al. 2014). Both 15D and the questionnaire on health care services 
were posted to the patients before sialendoscopy and three and twelve months 
postoperatively.  
4.2.4 Intervention, randomization, and outcomes (III) 
Before or during the sialendoscopy, the patients were randomized at a ratio of 1:1 
in a double-blind fashion to receive either 1 mL of isotonic saline solution (n=24) 
or 1 mL of hydrocortisone 125 mg/mL (n=25) intraductally. The study medicine 
was given to patients after sialendoscopy. Before, the gland was massaged until 
emptied of the rinsing solution. In cases of bilateral symptoms, sialendoscopy was 
performed for the gland with more symptoms, and in some cases with equal 
symptoms, for both glands with an identical technique. Gland massage was 
recommended from the following day on.  
The primary outcome of the study was defined as the efficacy of the 
sialendoscopy to reduce the symptoms of recurrent parotitis. The secondary 
outcome was defined as the ability of a single-dose hydrocortisone injection, in 
conjunction with sialendoscopy, to reduce the symptoms of recurrent parotitis 
more than sialendoscopy alone. The primary and secondary outcomes, the 
reduction of symptoms, were based on the symptom frequency as well as severity 
measured by the VAS.  
As this methodology had not been used in prior studies, it was difficult to 
estimate the average VAS scores and standard deviation (SD) of VAS scores for 
this patient group, making it challenging to perform accurate power calculations 
beforehand. As research proceeded, especially the postoperative VAS score 
proved to be highly variable with high SD, and it revealed that the size of the study 
group should have been significantly larger to disclose a 20% difference in the 
postoperative VAS scores between placebo and steroid groups. However, when a 
20% decrease in the postoperative VAS score was considered significant for the 
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primary outcome using 90% power, the whole study population was calculated to 
be sufficient.  
4.3 Statistical analysis 
In study I, Pearson’s chi-squared test was used to calculate correlations between 
categorical variables, and the Mann-Whitney U test was used to compare non-
normally distributed continuous variables between successful and unsuccessful 
sialolith removal.  
In study II, Pearson’s chi-squared test was used to compare categorical 
variables among patients’ answers. Spearman’s rank correlation was used to 
determine the correlations between non-normally distributed variables and 
patients’ answers and the differences of mean systolic and diastolic blood 
pressures, and the mean pulse between pre- and intraoperative values was 
determined with a paired sample t-test. 
In study III, the Wilcoxon non-parametric signed-rank test was used to 
determine the difference between symptom frequency and VAS scores before and 
after sialendoscopy. The Analysis of Covariance Report was used to determine the 
correlation between categorical variables and VAS change, and Spearman’s rank 
correlation test determined it between continuous non-parametric variables and 
VAS change. Either Pearson’s chi-squared test or Fisher’s exact test was used to 
compare categorical variables between placebo and steroid groups and the 
independent samples t-test for continuous variables. The frequency of symptoms 
and VAS scores were compared between placebo and steroid groups using an 
equal-variance t-test and Analysis of Covariance Report. 
In study IV, either Pearson’s chi-squared test or Fisher’s exact test were used 
to evaluate the categorical risk factors of complications, and the Equal-Variance 
t-test evaluated the continuous variables.  
In study V, Pearson’s chi-squared test or the independent samples t-test was 
carried out to compare patient characteristics between respondents and non-
respondents. The statistical significance of the difference in the mean 15D scores 
and costs between different groups was analyzed with an independent samples t-
test and the significance between baseline and follow-up 15D scores with a paired 
samples t-test 
The NCSS statistical software version 8 (NCSS Inc., Kaysville, UT, USA) or 
SPSS version 22 (SPSS Inc., Chicago, IL, USA) were used for the statistical 
analyses. P-values < 0.05 were considered to be significant.  
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4.4 Ethical considerations 
All studies were performed in accordance with the Declaration of Helsinki, Good 
Clinical Practice guidelines. Written informed consent was obtained from all the 
patients participating in studies III and IV. In the questionnaire studies II and V, 
the completion and return of the questionnaires were interpreted as permission 
to participate in the study. The protocols of studies II, III, IV, and V were 
approved by the Research Ethics Committee of the HUS. Since study I was 
retrospective and no patient contacts related to the study were made, ethics 
approval was not required.   
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5 RESULTS 
5.1 Patients’ characteristics (I–V) 
The mean age of the patients varied from 46 to 53 years, and the majority of 
patients were women (61–69%). Studies I and V also consisted of children. In 
study III, all the patients suffered from chronic recurrent parotitis and, in 
addition, four patients also had submandibular gland symptoms. In the other 
studies, a slight majority of patients had submandibular problems (54–56%). 
About half the sialendoscopies were performed in the parotid glands and half in 
the submandibular. In studies I and III, the most common symptom was swelling 
with or without pain in 90–100% of the patients. In addition, 16–29% had 
suffered from bacterial infections. In study I, 39% of patients had symptoms for 
less than one year, 37% one to five years, and 23% over five years, while in study 
III, the mean duration of symptoms was 7.2 years (range 0.5–41).  
According to study IV, the majority of sialendoscopy patients were in good 
health, with only a small number suffering from a severe systemic disease limiting 
their activity; 45% of patients had an ASA class I, 45% an ASA class II, and 10% 
an ASA class III, while 55% had CCI 0, 24% had CCI 1, 9% had CCI 2, and 12% 
had CCI 3 or more. Patients who suffered from chronic recurrent parotitis in study 
III smoked tobacco more often than patients in study IV. Smoking was not 
significantly related to any particular diagnosis in study IV (p=0.48). Sialadenitis 
was related to some autoimmune disease in 12 patients (5.3%) in an unselected 
cohort of 228 patients (study I), and in 6 (12%) patients with chronic recurrent 
parotitis (study III). The patients’ characteristics are presented in Table 3.  
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Table 3. Characteristics of patients 
 Study I Study II Study III Stydy IV Study V 
Patients, n 228 89 49 118 260 
Mean age, years (range) 46 (4–81) 50 (16–81) 53 (21–75) 47 (19–86) 46 (4–86) 
Gender, n (%)      
Female 138 (61) 50 (56) 33 (67) 81 (69) 171 (66) 
Male 90 (39) 39 (44) 16 (33) 37 (31) 89 (34) 
Tobacco smoking, n (%)      
Yes, currently - - 20 (41) 36 (31) - 
Earlier - - 11 (22) 28 (24) - 
No - - 16 (33) 51 (43) - 
Unknown 228 (100) 89 (100) 2 (4) 3 (3) 260 (100) 
Symptoms, n (%)      
Swelling 206 (90)  -  49 (100)  -   - 
Pain 50 (22)  -  19 (39)   -  - 
Recurrent bacterial infections 66 (29)  - 8 (16)   -  - 
Other 3 (1.3)  - 0 (0)  -  - 
Gland, n (%)      
Parotid 106 (46) 43 (48) 49 (100) 53 (45) 114 (44) 
Submandibular 122 (54) 46 (52) 0 (0) 65 (55) 146 (56) 
Diagnosis, n (%)      
Sialolithiasis 84 (37) 31 (35) 0 (0) 50 (42)  111 (43) 
Sialadenitis 112 (49) 42 (47) 49 (100) 45 (38) 129 (50) 
Stricture 28 (12) 16 (18) 0 (0) 20 (17) 19 (7.3) 
Other 4 (1.8) 0 (0) 0 (0) 3 (2.5) 1 (0.4) 
5.2 Sialendoscopy findings and outcomes (I–V) 
The most common endoscopic finding in studies I and IV was a sialolith(s) in 37% 
and 42% of patients, respectively. The second most common finding was 
inflammatory changes (debris and/or sialodochitis) in 31–32% of patients, while 
strictures or stenosis were confronted in 23–25%. Normal findings were detected 
in 17–23% of patients.  
In recurrent parotitis, inflammatory changes (mucus plugs or sialodochitis) 
were detected in 67% of patients and strictures or stenosis in 59%, while 24% of 
patients had only a small amount of exudate in an otherwise normal ductal system 
(study III).  
The postoperative diagnoses were sialadenitis in 38–50%, sialolithiasis in 35–
43%, and stricture in 7.3–18% of the patients (studies I, II, IV, and V). In a few 
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cases, the postoperative diagnosis turned out to be a disorder not manageable 
with sialendoscopy, e.g., cysts, sialosis, or unspecific facial pain. Most sialoliths 
were in the submandibular glands, while the strictures/stenosis and 
inflammatory changes were more common in the parotid glands. In study III, all 
patients had diagnosed chronic recurrent parotitis based on the symptoms, 
imaging, and endoscopy findings, even though strictures and stenosis were 
common endoscopy finding in this group. The postoperative diagnoses are shown 
in Table 3. 
In study I, the outcome of patients was evaluated at a follow-up visit or by a 
phone call and ranged based on the main endoscopic finding. The mean follow-
up was 18.6 months (range, 0.7–36.2) and 16 (7%) patients were lost in the follow-
up. After successful sialolith removal, symptoms resolved in 82% and improved 
in 13% of patients. In 5%, the symptoms continued the same. Re-sialendoscopy 
was performed on two patients. After unsuccessful sialolith removal, 50% of 
patients still reported resolution of symptoms, while in the other 50%, the 
symptoms did not improve. Five patients underwent submandibulectomy and a 
combined approach was scheduled for one. The majority of patients with 
stricture(s) or stenosis reported resolution (40%) or improvement (40%) of 
symptoms, but in 18% of these patients, the symptoms relapsed during the 
following months. No improvement was seen in 21% of patients. Four patients 
needed submandibulectomy, four were scheduled for a re-endoscopy, and nine 
received corticosteroid intraductally at an outpatient clinic. Symptoms resolved 
(30%) or improved (56%) in 86% of patients with inflammatory changes as the 
only finding but relapsed later in 38% of them. Symptoms persisted in 14%. One 
patient underwent submandibulectomy and the other one Jacobson’s 
neurectomy, two were treated with botulinum toxin injections, and ten with 
intraductal corticosteroid injections. A re-endoscopy was scheduled for 10 
patients. From the patients with normal endoscopic findings, 71% got relief for 
their symptoms, but the symptoms relapsed later in 12%. No improvement was 
noticed in 29%. Two patients underwent submandibulectomy, but the symptoms 
continued after the procedure in the other one, and trigeminal neuralgia or 
unspecific facial pain was suspected. One patient underwent both botulinum 
toxin injection and Jacobson’s neurectomy, four got corticosteroids intraductally, 
and one re-endoscopy was scheduled.  
In study III, sialendoscopy reduced the symptoms of chronic recurrent 
parotitis, but the permanent symptom resolution was rare. Both mean VAS score 
and frequency of symptoms decreased significantly at 3, 6, and 12 months 
postoperatively (p<0.001). At 3 months postoperatively, 27% of patients were 
symptom-free, symptoms had decreased significantly in 31%, decreased slightly 
in 20%, remained unchanged in 18%, and increased slightly in 4%. At 12 months 
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postoperatively, only one (2%) patient had been symptom-free during the whole 
follow-up time. Patients with higher VAS scores preoperatively had a smaller VAS 
score change postoperatively (p=0.024), while gender, age, concurrent 
autoimmune disease, tobacco smoking, teeth status, duration of symptoms, 
endoscopic finding, or opening of a stricture had no significant impact on the VAS 
score. Hydrocortisone did not improve the postoperative results significantly 
when measured by VAS score change or symptom frequency at 3 and 12 months 
postoperatively.     
5.3 Sialoliths (I, IV) 
In study I, most sialoliths were over 4 mm in diameter (49/84, 58%;  size 
unknown in 12/84, 14%) ; they were situated most often in the hilar area in the 
submandibular glands (44/71, 62%) and in the main duct in the parotid glands 
(6/13, 46%). Of all sialolithiasis patients, 19% (16/84) had more than one sialolith. 
Sialolith(s) removal was successful in 77% (65/84) of cases. The purely 
endoscopic sialolith removal was possible only in 23% (19/84) of all cases; 52% 
(12/23) of sialoliths that were 4 mm or under were endoscopically removable, 
while the rate was only 8% (4/49) in sialoliths over 4 mm. In three cases with 
successful endoscopic sialolith removal, the size of the sialolith was not known.  
Endoscopy-assisted transoral sialolith removal was used successfully in 55% 
(46/84) of all cases, mostly for sialoliths over 4 mm in diameter and located in 
the ductal or hilar areas. In three cases, the parotid stone was successfully 
removed transcutaneously with a combined technique.  
Sialolith removal was unsuccessful in 19 cases (23%). Two times, the 
sialendoscopy-assisted transoral removal of the sialolith failed because of difficult 
anatomic conditions and multiple sialoliths, and in 17 cases, the endoscopic 
removal failed because of the adherence of the sialolith. In these cases, a 
sialendoscopy-assisted transoral approach was not tried mostly due to a hilar or 
intraglandular sialolith and difficult anatomic conditions, or according to the 
patient’s wishes. A more proximal location of the sialolith was related to 
unsuccessful sialolith removal (p=0.009), while the size of the sialolith or the 
duration of the symptoms had no effect on the success rate when noticed in both 
endoscopic and combined procedures (p=0.42 and p=0.53, respectively). 
However, the larger diameter of sialoliths (over 4 mm) related significantly more 
often to unsuccessful endoscopic sialolith removal (p<0.001). 
In study IV, sialoliths were eventually successfully removed in 84% (42/50) of 
patients, with the other 16% (8/50) remaining unsuccessful. Four patients needed 
a second procedure to ensure the successful removal, so altogether, sialolith 
removal failed in 12 sialendoscopies (12/54, 22%) during the study period. A 
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purely endoscopic sialolith removal was successful in only 6 patients (12%), 
having failed 11 times due to stone adherence. In 36 patients (72%), a 
sialendoscopy-assisted combined approach was necessary for successful sialolith 
removal; five of those were sialendoscopy-assisted transcutaneous approaches of 
parotid stones. One-time sialendoscopy-assisted transoral removal of the 
submandibular sialolith failed because there were multiple sialoliths and a 
difficult location.  
5.4 Complications (I, IV, V) 
A complication was confronted in 15% (21/140) of sialendoscopies in a 
prospective observational study (IV), and in 8.3% (22/266) in a retrospective 
study (I). In both studies, the most common complication was an infection in 
6.4% (9/140) and 7.1% (19/266) of cases. In study IV, all infections were related 
to the interventional sialendoscopy, and most occurred in the submandibular 
glands (8/9, 89%). Sialolithiasis increased the risk of infection significantly 
(p=0.012), and both a retained sialolith and intraoral stone removal from the 
posterior region were independent risk factors for the infection (P=.004 and 
P=.048, respectively) while prophylactic antibiotics in sialolithiasis patients did 
not decrease the rate of infections (p=0.410). In both studies I and IV, two 
patients needed intravenous antibiotics and hospitalization, while the others were 
treated with a peroral course of antibiotics.  
All the complications encountered in study IV and the treatment used are 
represented in Table 4. In all, the risk factors for complications were sialolith 
removal (p=0.001) and stricture dilatation (p=0.032). Also, longer operation 
times (p=0.001) and GA (p=0.011) were related to increased complication risk. 
The surgeon experience, patient age, ASA class, CCI, or tobacco smoking did not 
correlate with complication risk.  
In study V, a complication that caused direct hospital costs occurred in 8.1% 
of sialendoscopies. The mean hospital cost per complication (€922, SD €1309, 
range €110–4425) was significantly higher in patients with sialolithiasis (n=16, 
€1131, SD €1444, range €110–4425) compared to patients with other diagnoses 
(n=5, €255, SD €130, range €110–435) (p=0.029), and most of the complications 
were related to the sialolith removal or the attempt. 
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Table 4. Frequency and treatment of complications of the 140 operated glands; 67 parotid 
and 73 submandibular glands  
 
5.5 Local anesthesia (II) 
LA or LAS was the most common anesthetic method in 89–96% of all 
sialendoscopies in studies I–V. In study II, 89 patients estimated their 
postoperative sensations about the LA/LAS procedure, and the answers are 
presented in Figure 5. According to the ASA depth of sedation scale, 20% of 
patients had no sedation, 72% had minimal sedation with small doses of fentanyl 
with or without diazepam, and 8% had moderate sedation with propofol. The 
mean systolic (135 mmHg vs. 138 mmHg) and diastolic (78 mmHg vs. 84 mmHg) 
blood pressures of patients were lower during the operation when compared to 
the preoperative situation (p=0.039 and p<0.001, respectively), while no 
significant difference was noticed in the mean pulse (72 bpm vs. 71 bpm) 
(p=0.84). Over half the patients (53%) experienced major or moderate 
nervousness before the operation. Older patients were less nervous compared to 
younger ones (p=0.017), and men were less nervous than women (p=0.0012). 
Complication All, n (%) Parotid, n (%) Submandibular, n (%) Treatment 
Infection 9 (6.4) 1 (1.5) 8 (11) 
Per oral antibiotics  
(n=7) 
Hospitalization 
and intravenous 
antibiotics (n=2) 
Ductal perforation 4 (2.9) 1 (1.5) 3 (4.1) 
Normal 
postoperative care 
with follow-up 
(n=4) 
Swelling 3 (2.1) 0 (0) 3 (4.1) 
Conservative 
management 
(n=2) 
Per oral steroids 
for 7 days (n=1) 
Lingual nerve 
dysfunction 
(temporary) 2 (1.4) 0 (0) 2 (2.7) 
Analgesics (NSAIDs 
and paracetamol) 
with follow-up 
(n=2) 
Basket 
entrapment 2 (1.4) 2 (3.0) 0 (0) 
Removal of 
entrapped basket 
and sialolith 
through transfacial 
approach (n=2) 
Facial nerve 
dysfunction 
(temporary) 1 (0.7) 1 (1.5) 0 (0) 
Spontaneously 
resolved within 5 
hours (n=1) 
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However, the operation was well-tolerated, and the majority of patients estimated 
the level of discomfort and pain during the operation as mild or none (86% and 
89% of patients, respectively). Older patients felt less discomfort compared to 
younger ones (p=0.036). Patients who underwent sialolith removal through a 
transoral incision estimated the level of discomfort and pain to be higher than 
others, but statistical significance was reached only after combining the major and 
moderate answers (p=0.048 and p=0.053, respectively). The trend for an 
increased level of pain with longer operation times was observed (p=0.056). After 
the operation, 87% of patients estimated the level of pain as mild or none, and the 
majority of patients did not need any pain medicines postoperatively at a hospital. 
Men experienced less pain than women (p=0.034), and patients whose sialoliths 
were removed using a transoral incision experienced more pain than others 
(p=0.016). The majority of patients (97%) would be willing to undergo LA/LAS 
sialendoscopy again in the future if necessary.  
  
  
Figure 5 Questions presented to patients after sialendoscopy and patient responses on 
a scale from major to none.  
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5.6 HRQoL of patients measured with 15D questionnaire 
(V) 
At the baseline, the mean total HRQoL score of 74 patients was clinically but not 
statistically significantly lower than that of the age- and gender-matched general 
population (0.909, SD 0.079 vs. 0.925, SD 0.025, p=0.100). Patients had 
significantly worse scores 0n 2 of 16 dimensions: “discomfort and symptoms” 
(p=0.002) and “distress” (p=0.032). Among the 51 patients who returned all 
three questionnaires, they had improved in “discomfort and symptoms” at 3 
months (p=0.014) and at 12 months (p=0.039) postoperatively significantly, and 
the total HRQoL score improved in patients with sialolithiasis at 3 months 
postoperatively (p=0.041). At the 3- and 12-month follow-ups, submandibular 
gland patients felt less “discomfort and symptoms” compared to parotid gland 
patients (p=0.022 and p=0.021, respectively). Those with sialolithiasis were less 
depressed and distressed at baseline (p=0.013 and p=0.035, respectively) and 
experienced less depression (p=0.002), distress (p=0.006), and discomfort and 
symptoms (p=0.046) at 3 months postoperatively compared to patients with 
other diagnoses. The mean 15D profile of patients based on the postoperative 
diagnosis is presented in Figure 6.  
 
 
Figure 6a The mean 15D profile of patients with sialolithiasis and other diagnoses before 
sialendoscopy. 
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Figure 6b The mean 15D profile of patients with sialolithiasis and other diagnoses at 3 
months postoperatively. 
 
Figure 6c The mean 15D profile of patients with sialolithiasis and other diagnoses at 12 
months postoperatively.  
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5.7 Costs (V) 
The mean total hospital costs analyzed from 260 patients during the two-year 
time period (one year prior to sialendoscopy and one year after sialendoscopy) 
were €2265 per patient (SD €968, range €1280–7880), the mean costs of the 
sialendoscopic-procedure(s) were €1673 per patient (SD €466, range €1170–
4373; €1593 per procedure), and the mean costs of the clinical encounters (also 
containing phone contacts and laboratory and imaging costs) were €416 per 
patient (SD €378, range €0–2215). The mean total hospital costs, mean costs of 
sialendoscopy, and mean costs of complications were statistically significantly 
higher among patients with sialolithiasis compared to patients with other 
postoperative diagnoses (p=0.014, p<0.001 and P=0.029, respectively), while the 
mean costs of the clinical encounters were higher in patients without sialoliths 
(p=0.012). Submandibular gland patients had higher sialendoscopy-related costs 
(p=0.006), but the costs of clinical encounters (p=0.006) were lower when 
compared with parotid gland patients (Figure 7). 
The questionnaire concerning the use of primary health care services related 
to salivary gland disease during the preceding three months revealed that a 
significant decrease in the mean total costs occurred from baseline to 12 months 
postoperatively (p=0.001), and from the individual costs of doctor visits in private 
or public primary health care, hospital costs and the costs of other contacts 
decreased significantly from baseline to 12 months postoperatively (p<0.01) 
among 43 respondents. 
 
Figure 7 Hospital costs. 
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6 DISCUSSION 
6.1 Sialendoscopy findings and outcomes (I, III, IV) 
The most common endoscopic findings (studies I and IV) were sialolithiasis 
followed by inflammatory changes and strictures or stenosis. Sialoliths were more 
frequent in the submandibular glands, whereas stenosis, strictures, mucus plugs, 
and signs of sialodochitis existed more often in parotid glands, which is in line 
with other studies (Chuangqi et al. 2013, Gallo et al. 2016). Ductal strictures or 
stenosis are the second-most frequent cause of obstruction in the salivary glands, 
especially seen in cases of unclear swelling (Ngy et al. 2007, Gillespie et al. 2011, 
Vashishta & Gillespie 2013). In many cases, strictures or stenosis occur together 
with inflammatory changes and are related to the chronic inflammatory process 
(Nahlieli et al. 2006a).  
The most frequent endoscopic findings in chronic parotitis were mucus plugs 
followed by strictures with or without dilatation of the duct, stenosis, and 
sialodochitis. A pale matte appearance of the duct with mucus plugs and strictures 
or stenosis has been described in both adults and children with chronic parotitis 
(Nahlieli et al. 2004a, Shacham et al. 2009). Sialendoscopy findings confronted 
in our study in different salivary gland disorders are shown in Table 5. 
In total, 17–24% of our patients did not have any specific endoscopic findings, 
except for a small amount of exudate in some cases. This is more than in many 
previous studies (Koch et al. 2005, Chuangqi et al. 2013, Vashishta & Gillespie 
2013). This might be due to less severe disease in some patients or it may be the 
interpretation of the surgeon. The majority of these patients (71%), however, 
benefitted from the sialendoscopy (study I). In these cases, simply the dilatation 
of the duct might have helped, and in some cases, there might have been a placebo 
effect.   
Treatment of ductal strictures and stenosis endoscopically or with an 
endoscopy-assisted transoral approach has high success rates of 80–100%, with 
improvement of symptoms in 75–95% of cases (Nahlieli et al. 2001, Ardekian et 
al. 2010, Koch et al. 2012a, Koch et al. 2012b, Kopec et al. 2013b). However, most 
patients report some degree of persistent symptoms or recurrence of symptoms 
postoperatively, which is in line with our results (Koch et al. 2014, Delagnes et al. 
2017b); over 60% of stricture/stenosis patients had some postoperative 
symptoms, and recurrences occurred in 18% (study I). Unlike in many other 
studies, we did not have balloon dilators available, and we did not use transoral 
surgery for strictures, excluding papillotomy. 
In study I, 70% of patients with inflammatory changes had continuous 
symptoms postoperatively, even though mostly to a lesser degree, and 38% had a 
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relapse of symptoms (study I). However, contrarily, 86% had a resolution or some 
improvement of their symptoms, which is comparable to the literature (Vashishta 
& Gillespie 2013).  
In study III concerning chronic recurrent parotitis, 78% of patients got some 
relief for their symptoms three months postoperatively. For the rest, the 
symptoms remained unchanged or increased. Patients with more severe 
preoperative symptoms received less benefit from the sialendoscopy, which might 
be explained by more aggressive or advanced disease. We did not find any 
significant benefit from a ductal single-dose steroid given after sialendoscopy 
compared to sialendoscopy with saline irrigation only. However, few studies have 
suggested that sialendoscopy followed by repeated ductal steroid irrigations 
might produce a better outcome than sialendoscopy alone in patients with chronic 
inflammation (Capaccio et al. 2017, Capaccio et al. 2018a). In a study of SS 
patients, no significant difference was found between sialendoscopy and 
sialendoscopy+steroid groups on salivary flow and xerostomia (Karagozoglu et al. 
2018). 
Table 5. Sialendoscopy findings in different salivary gland disorders  
Disorder General sialendoscopy 
findings 
Other possible sialendoscopy 
findings 
Chronic sialadenitis 
(e.g., chronic recurrent 
parotitis/JRP/RAI-
induced 
sialadenitis/Sjögren’s 
syndrome) 
mucus plugs/fibrinous 
exudate, a pale, avascular 
matte appearance of the duct, 
strictures and/or stenosis of 
the duct, irregular 
enlargement or dilatation of 
the duct 
erythematous/irrigated duct with 
small ecchymosis, atrophic ducts 
Obstructive 
sialadenitis 
adhesive or floating sialolith, 
stricture or stenosis of the 
duct, mucus plugs 
kink of the duct, polyp 
Duct stricture a short, web-like or fibrotic 
segment of intraductal 
narrowing/scar, complete 
blockage of the duct 
local dilatation of the duct, 
mucus plugs/exudate 
Duct stenosis a long/diffuse narrowing of 
the ductal lumen  
local dilatation of the duct, 
mucus plugs/exudate 
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6.2 Sialoliths (I, IV) 
In our study, most submandibular stones were located in the hilar area, while 
parotid stones were more often found in the main duct, which is in line with the 
literature (Yu et al. 2010, Zenk et al. 2012, Schwartz et al. 2015a, Kondo et al. 
2018). In our studies, the sialoliths were successfully removed with an 
interventional sialendoscopy or with incisional sialolithotomy in 77–84% of 
cases, but only in 12–23% of cases, the removal was possible purely 
endoscopically. In the literature, the overall success rates, from 76–95%, have 
been published depending on the study population, experience of surgeons, and 
available instrumentation (Combes et al. 2009, Yu et al. 2010, Bowen et al. 2011, 
Liu et al. 2013, Pace et al. 2014, Schwartz et al. 2015a, Kopec et al. 2016, Schapher 
et al. 2017). Reported success for endoscopic sialolith removal varies between 
29% and 89%, which is higher than in our findings (Nahlieli et al. 2006a, 
Papadaki et al. 2008, Yu et al. 2010, Bowen et al. 2011, Luers et al. 2011, Kopec et 
al. 2016). However, in many studies, the instrumentation includes lasers or 
intraductal lithotripters, which were not available in our studies (Nahlieli et al. 
2006a, Papadaki et al. 2008).  
A large study of more than 1000 sialolithiasis patients showed that only 5% of 
submandibular and 22% of parotid sialoliths were removable purely 
endoscopically with a basket, miniature drill, or forceps (Zenk et al. 2012). In 
another study, 13% of submandibular stones and 38% of parotid stones were 
successfully removed with interventional sialendoscopy alone, while the rest 
required incisional sialolithotomy or gland excision, which is consistent with our 
results (Fabie et al. 2019). The size limit for successful endoscopic stone removal 
is considered to be 3–5 mm. Generally, stone crushing of some form is needed for 
larger stones (Marchal & Dulguerov 2003, Zenk et al. 2012).  
The most common causes for unsuccessful sialolith removal were adherence 
of the sialolith and proximal location. The prognostic factors for successful 
endoscopic removal of a sialolith are small size, good mobility, round or oval 
shape, and distal location (Luers et al. 2011, Cox et al. 2018). In Figures 8 and 9, 
a decision tree is presented for the management of parotid and submandibular 
salivary stones according to diameter and position of the stone based on our 
studies and previous literature. We have used endobuccal transmucosal duct 
incision for the removal of distal parotid stones, but some authors refrain from 
that in fear of duct stenosis (Witt et al. 2012). ESWL has been used successfully 
for the treatment of impacted sialoliths in both the submandibular and parotid 
glands (Escudier et al. 2010, Zenk et al. 2012), but it is not mentioned in our figure 
because ESWL is not available in Finland.  
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Figure 8 Decision tree for the best minimally invasive treatment of the parotid stones 
based on our study and literature.  
 
Figure 9 Decision tree for the best minimally invasive treatment of submandibular stones 
based on our study and literature.  
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6.3 Complications (I, IV, V) 
The complication rates for sialendoscopy and sialendoscopy-assisted operations 
range from 2–15%, being around 3–5% in larger series (Koch et al. 2005, Gillespie 
et al. 2011, Felton et al. 2012, Rasmussen et al. 2012, Nahlieli 2015, Gallo et al. 
2016). In some studies, failure to perform an intervention is defined as a 
complication, increasing the complication rates as high as 20–30% (Walvekar et 
al. 2008, Karagozoglu et al. 2017). According to the Clavien-Dindo Classification 
of Surgical Complications, failure to treat is not counted as a complication (Dindo 
et al. 2004). We used this definition in our prospective complication study. The 
relatively high rate of complications (15%) confronted in our fifth study might be 
related to the prospective setup, where all the complications were defined and 
prospectively registered before the study. In addition, the registration of 
postoperative swelling as a complication varies. Swelling of the gland is a natural 
reaction for the irrigation and usually resolves after a few hours to a few days 
(Nahlieli & Baruchin 2000, Koch et al. 2005). We classified postoperative 
swelling as a complication if it required treatment or was prolonged, but in many 
studies, it is probably not registered as a complication at all.  
The most common complications in sialendoscopy are perforations or 
strictures of the duct (Nahlieli et al. 2006a, Rasmussen et al. 2012, Nahlieli 2015, 
Gallo et al. 2016, Karagozoglu et al. 2017). In our study, postoperative infections 
were the most ruling (6–7%), while stricture was confronted only once (study I). 
However, strictures may be underdiagnosed since re-sialendoscopy was not 
performed on all patients with persistent symptoms.  
Postoperative infections were significantly associated with sialoliths. 
Sialendoscopy-assisted transoral sialolith removal from the posterior region and 
retained sialoliths after an unsuccessful removal attempt both predisposed to 
infections. In other studies, postoperative infection rates between 0% and 11% 
have been reported, mostly around 1% (Rasmussen et al. 2012, Nahlieli 2015, 
Gallo et al. 2016, Karagozoglu et al. 2017). Both pre- and postoperative antibiotics 
are widely used in sialendoscopy, and some authors also use postoperative 
steroids (Koch et al. 2005, Nahlieli et al. 2006a, Liu et al. 2009, Strychowsky et 
al. 2012, Nahlieli 2015). Interestingly, we found no association between 
prophylactic preoperative antibiotics and the rate of infections. One explanation 
may be the postoperative swelling of the duct with salivary stagnation, which 
might predispose to infection. To determine whether the use of antibiotics and/or 
steroids reduces the rate of postoperative infections in interventional 
endoscopies, more randomized, controlled studies are needed. We do not 
recommend routine antibiotics or corticosteroids after diagnostic sialendoscopies 
since practically no postoperative infections were noted in this group. 
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Other complications confronted in our studies were transient lingual nerve 
paresthesia, ranula formation, basket entrapment, salivary fistula, and temporal 
weakness of the marginal branch of the facial nerve. They were also associated 
with interventional endoscopies in most cases. Permanent lingual nerve 
paresthesia after transoral submandibular sialolith removal, as well as lingual 
nerve damage during purely intraductal endoscopic procedures, are very rare 
(Nahlieli 2009, Gallo et al. 2016). In addition, ductal avulsion (Walvekar et al. 
2008), hemorrhage (Nahlieli et al. 2006a), sialoceles (Carta et al. 2017), and 
extravasation of the irrigation fluid leading to the pharyngeal swelling and airway 
obstruction (Papadaki et al. 2008, Martins-Carvalho et al. 2010) have been 
reported but not encountered in our studies.  
The costs of complications varied widely in study V with higher costs related 
to sialolithiasis. The need for an inpatient treatment or re-operation(s) among 
some patients with infection, salivary fistula, or ranula increased the costs 
significantly. 
 
6.4 Tolerability of sialendoscopy (II) 
The type of anesthesia depends on many factors, such as invasiveness of the 
operation, the surgeon’s personal preferences, site and painfulness of the surgery, 
and patient-dependent factors. The patient’s compliance is the key to the success 
of LA or LAS. In sinonasal surgery, LA/LAS was associated with shorter operation 
time, faster patient recovery, and shorter hospital stay when compared to GA 
procedures (Fedok et al. 2000, Daskaya et al. 2014). In addition, the side effects 
of GA can be avoided in LA and LAS. 
Our study shows that sialendoscopy is well tolerated in adult patients under 
LA/LAS with only minimal experience of pain and discomfort. Similar results 
have been reported in a few other studies assessing patients’ satisfaction after 
LA/LAS sialendoscopy (Luers et al. 2012b, Bawazeer et al. 2018). Patients 
experienced more pain and discomfort during the operation and postoperatively 
if the sialolith was removed via a transoral incision. However, almost all patients 
(97%) agreed to a new LA/LAS procedure if necessary. In other studies, patients 
have also favored LA/LAS over GA (Knezevic et al. 2012). While LA can give a 
patient a sense of control during the procedure, others can regard the idea of LA 
as very stressful and unpleasant. During the study period, six patients (4.5%) had 
major anxiety regarding the operation, and they requested a GA procedure. A GA 
procedure was also planned in advance for seven sialolith patients whose 
procedures were expected to be complex and long, which might have caused some 
bias in the study outcome. The operative success rate and outcome seem equal in 
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LA/LAS and GA procedures (Bawazeer et al. 2018). In our study, the operation 
time was shorter in LA/LAS procedures, while Bawazeer et al.’s (2018) study 
showed the contrary. However, in our study, more complex procedures were 
performed under GA than under LA/LAS. We excluded children from this study, 
but Konstantinidis and colleagues (2011) showed that diagnostic sialendoscopy 
can be performed under LA in children older than 8 years of age. 
The advantage of LA/LAS is that the personnel can tailor the degree of 
anesthesia to the needs of the patients. Most of the patients (72%) got a small 
dose(s) of fentanyl perioperatively, which was given to patients if any 
inconvenience or pain was detected. This might explain the decrease of mean 
systolic and diastolic blood pressure in patients, but it can also be noted in the 
rather low level of patient arousal and pain during the operation. 
6.5 HRQoL after sialendoscopy (V) 
We used a generic, self-administered, 15D HRQoL instrument in study V. 
Although no statistically significant difference was observed in the 15D score 
between the patients and the general population before the sialendoscopy, the 
difference was over 0.015, which has been estimated to be the minimal clinically 
important change, so it could be estimated that the HRQoL of patients with 
sialadenitis is slightly decreased when compared to the matched general 
population (Alanne et al. 2015). The overall HRQoL improved significantly only 
in patients with sialolithiasis at three months postoperatively, but not in others. 
In comparison, tonsillectomy patients had significantly decreased HRQoL when 
compared to the general population, and their HRQoL improved after 
tonsillectomy (Wiksten et al. 2013), while septoplasty patients had slightly better 
HRQoL than the general population preoperatively, and the HRQoL decreased 
after septoplasty based on the 15D questionnaire (Hytonen et al. 2012). However, 
the patient selection cannot be underestimated in surgical procedures since the 
HRQoL of septoplasty patients has shown to increase after septoplasty in other 
studies with more severe preoperative symptoms (Alakärppä et al. 2017).  
The subgroup analysis preoperatively and at three months postoperatively 
revealed that ailments in sialolithiasis patients may be less burdensome and the 
sialendoscopy more effective than in patients with other etiologies, which has also 
been noticed in other studies concerning HRQoL (Meier et al. 2015, Gillespie et 
al. 2015, Aubin-Pouliot et al. 2016b). This is not surprising, since the symptoms 
usually resolve after successful sialolith removal, while the patients with chronic 
sialadenitis, strictures, or stenosis have persistent or recurrent symptoms more 
often (Achim et al. 2017). However, unexpectedly, the HRQoL of sialolithiasis 
patients decreased again at 12 months postoperatively. This could be because of 
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only partial success in the sialolith removal in some patients, concurrent 
inflammatory disease, and/or the stenosis or appearance of other diseases or 
problems in some patients. Ryan et al. (2019) could demonstrate a durable, long-
term benefit from SASDS for sialolithiasis patients with both endoscopic and 
open techniques with only minor residual symptoms. Unlike the study by Meier 
et al. (2015), our results suggest that the parotid patients have more discomfort 
and symptoms postoperatively compared to submandibular patients. This may 
relate to the higher incidence of chronic inflammation and strictures in parotid 
glands.  
The 15D questionnaire failed to demonstrate any significant difference in 
dimension eating, even though the patients with obstructive sialadenitis could be 
assumed to have problems in this area. However, in the 15D questionnaire, this 
dimension measures the mechanical aspect of eating rather than symptoms while 
eating. 
6.6 Costs of sialendoscopy (V) 
Only a few studies have concerned the costs and cost-effectiveness of 
sialendoscopy (Shashinder et al. 2011, Rosbe et al. 2015, Ong et al. 2017, 
Kowalczyk et al. 2018). The mean cost of sialendoscopy (€1673) comprised a 
substantial part of the mean total hospital costs (€2265) of treated patients during 
the two-year time period in our study. The sialolithiasis patients needed more GA, 
overnight stay at a hospital, or a second endoscopic procedure to ensure 
successful stone removal, and a higher rate of complications was encountered 
within these patients, which explains the higher costs of care and sialendoscopy 
within this group. The mean costs of clinical encounters were higher in patients 
without sialoliths as well as in parotid patients, which might be related to the over-
representation of chronic sialadenitis with ongoing symptoms requiring 
ambulatory interventions.  
We were not able to assess the cost-effectiveness of sialendoscopy since we did 
not have a control group in our study. Few retrospective studies have tried to 
estimate this. According to Rosbe et al. (2015), the treatment of JRP is much more 
expensive with sialendoscopy than with conservative treatment with the same 
results, while Ong et al. (2017) deduced that the costs of transfacial sialendoscopy-
assisted removal of parotid sialoliths were much lower and the procedure much 
faster than parotidectomy. However, since in Finland a parotidectomy is rarely 
performed because of sialolithiasis nowadays, a more appropriate and interesting 
benchmark would be conservative treatment, Jacobson’s neurectomy, or 
botulinum toxin therapy. In our study, the sialendoscopy-assisted treatment of 
sialolithiasis (mean cost €1863) was less expensive compared to the 
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submandibulectomy (mean cost €2293). Shashinder et al. (2011) estimated that 
the most cost-effective treatment of sialolithiasis is a polyclinic transoral sialolith 
removal, but the study lacked a control group. 
In our study, most procedures were performed in a fully equipped operating 
theater, but a few took place in a smaller polyclinical operating room. According 
to Coniglio et al. (2019), in-office–based sialendoscopy might reduce the time 
burden and health care charges of patients compared to the operating theater 
procedure. 
6.7 Limitations of the study 
Since the study I was retrospective, some medical records were insufficient and 
lacked the surgeon’s opinion about the main endoscopic findings. Also, some 
follow-up data were lost.  
In study II, the lack of a validated questionnaire made comparing our results 
to other studies and surgical procedures difficult. In addition, since the study 
protocol was not randomized, we could not compare the LA/LAS sialendoscopies 
to GA ones and find the best anesthetic method.  
Study III lacked a true control group. Both study groups underwent a 
procedure, and a placebo effect is always possible after an intervention. A lack of 
a validated symptom outcome questionnaire can also be seen as a limitation, and 
an assessment of symptoms during the last three months may lead to some 
memory bias. We were able to recruit only a limited number of patients due to the 
relatively low rate of patients with chronic recurrent parotitis, and the number of 
patients was not sufficiently powered to determine a clinical difference between 
the steroid and non-steroid groups, which may cause a false-negative result (type 
II error).  
In study IV, the relatively small study population and lack of routine control 
visits were the main limitations. However, the patients got thorough information 
about the normal postoperative recovery and symptoms of common 
complications and were engaged to contact the emergency department of our 
hospital if they suspected any deviation from normal recovery.  
In study V, the patients’ response rate was disappointingly low, which may 
lead to over- or under-representation of patients whose HRQoL was impaired 
because of recurrent sialadenitis. Moreover, the lack of a control group and 
validated salivary gland–specific HRQoL questionnaire can be seen as a 
limitation.  
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6.8 Future aspects 
Nowadays, the focus of the treatment of salivary glands’ obstructive and 
inflammatory pathologies is to preserve the gland and its function with minimally 
invasive methods. This reflects the wider trend in surgery, which, with the help of 
improved optical technologies combined with smaller and less invasive incisions, 
is focused on improving function and speeding up the recovery. A growing interest 
against endoscopic and other minimally-invasive approaches to treat benign 
salivary gland disorders is detected worldwide. As this improves the treatment 
opportunities in many cases, the right patient selection becomes more important 
in helping to keep the growing health care costs in control and to get the best 
benefit from the new treatment methods. Thus, the efficacy and cost-effectiveness 
of sialendoscopy and sialendoscopy-assisted operations in different patient 
groups with prospective, controlled studies are definitely worth future studies. 
Furthermore, many procedure-related issues and guidelines still need to be 
examined with no consensus existing, e.g., regarding appropriate anesthesia, the 
role of prophylactic antibiotics, stents, or corticosteroids in sialendoscopy.  
In turn, the development of imaging methods permits more accurate 
diagnostics, making the preoperative planning easier. MR virtual endoscopy 
seems to be an effective and noninvasive diagnostic method for evaluating the 
endoluminal anatomy and pathologies of the salivary duct (Su et al. 2006), and 
combined CT navigation and the sialendoscopy-assisted approach have been used 
successfully in the removal of deep intraparenchymal, nonpalpable, and impacted 
parotid stones (Capaccio et al. 2018). Although this means more technical efforts 
and costs, it can be an acceptable solution for selected patients and also a cost-
effective treatment compared to traditional surgery or conservative treatment 
with decades of persisting symptoms. 
In Figure 10, we present an algorithm for the modern treatment of salivary 
gland swelling based on our experience and literature.  
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7 CONCLUSIONS 
1. Endoscopic stone removal is usually possible with a basket only if the 
stone is mobile and its diameter is under 5 mm. In cases of larger or 
attached stones, the crushing or combined approach is needed for 
successful removal. Sialendoscopy improves the symptoms of chronic 
sialadenitis and strictures/stenosis, but some residual symptoms are 
common and recurrences happen often. 
 
2. Most sialendoscopies can be performed under LA/LAS with low patient 
discomfort and pain. 
 
3. Sialendoscopy effectively reduces the symptoms of chronic recurrent 
parotitis in adults. A single-dose steroid injection concomitant to 
sialendoscopy provided no additional benefit for the symptoms of chronic 
recurrent parotitis in this study. 
  
4. Complications of sialendoscopy are usually related to interventional 
sialendoscopy. Although most complications are minor, they may 
necessitate multiple patient contacts, further treatments, or 
hospitalization. The most common complication in this study was 
postoperative infection.  
 
5. Sialendoscopy improved the HRQoL only in sialolithiasis patients at the 
three-month follow-up when assessed with the 15D questionnaire.  
 
6. Sialendoscopic or sialendoscopy-assisted treatment of patients with 
sialolithiasis was more expensive than the sialendoscopic treatment of 
patients with strictures/stenosis and sialadenitis during the two-year time 
period.  
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APPENDICES 
Appendix 1. Questionnaire of tolerability of sialendoscopy under LA/LAS, 
study II 
 
The surgeon fills: 
LA / LAS / GA 
Parotid gland / submandibular gland                                 sin / dx / la 
Were there any interventions performed? If so, what?   
What anesthetics were used? 
 
The patient fills: 
Gender:    woman / man 
Age:  
Have you had an endoscopy of the salivary gland before? 
If yes, how many times? 
 
Before the operation, the level of nervousness I felt was: 
a. major  
b. moderate 
c. minor 
d. none 
After the operation, the pain I felt was:  
a. major 
 b. moderate 
 c. minor 
 d. none 
     During the operation, the discomfort I felt was: 
a. major / discomfort all the time 
 b. moderate / discomfort at times 
 c. minor / discomfort a few times 
 d. none / I did not feel discomfort at all 
    During the operation, the pain I felt was:  
a. major 
 b. moderate 
 c. minor 
 d. none 
 
I would agree / disagree to another operation again under local anesthesia, if necessary. 
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Appendix 2. Multiple-choice questionnaire, study III 
 
1.  How long ago did the parotid gland swell for the first time? _____________ 
 
2. How long did it take before the parotid gland swelled the second time? ___________ 
 
3. Parotid symptoms during the last 3 months: 
a.  Once a week or more often 
  b.  2 to 3 times a month 
  c.  Once a month 
  d.  More rarely 
  e.  No symptoms 
 
4. Parotid symptoms during the last 6 months: 
a.  Once a week or more often 
  b.  2 to 3 times a month 
  c.  Once a month 
  d.  3 to 5 times during the last 6 months 
  e.  More rarely 
  f.  No symptoms 
 
5. Parotid symptoms during the last year: 
a.  Once a week or more often 
  b.  2 to 3 times a month 
  c.  Once a month 
  d.  3 to 5 times during the last 6 months 
  e.  More rarely 
  f.  No symptoms 
 
6. Symptoms have been all the time: 
a.  Only on the right side 
  b.  Only on the left side 
  c.  More on the right side, but also on the left side 
  d.  More on the left side, but also on the right side 
  e.  Equally on both sides 
 
7. Symptoms have been during the last 6 months: 
a.  Only on the right side 
  b.  Only on the left side 
  c.  More on the right side, but also on the left side 
  d.  More on the left side, but also on the right side 
  e.  Equally on both sides 
 
8. During the last 3 months, the symptoms have: 
a.  Finished 
  b.  Decreased significantly 
  c.  Decreased slightly 
  d.  Remained unchanged 
  e.  Increased slightly 
  f.  Increased significantly 
 
 
9. Estimate how severe the parotid symptoms have been during the last 3 months? Please mark 
on the line below the point that best represents your perception. 
 
                 |--------------------------------------------------------------------------| 
             No symptoms                                                                                                                        The worst 
                  at all                                                                                                                           possible symptoms 
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Appendix 3. The 15-dimensional measure of health-related quality of life 
(15D), study V 
 
Please read through all the alternative responses to each question before placing a cross (x) against 
the alternative which best describes your present status. Continue through all 15 questions in this 
manner, giving only one answer to each. 
 
Question 1. Mobility 
1 ( ) I am able to walk normally (without difficulty) indoors, outdoors and on stairs. 
2 ( ) I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight 
difficulties. 
3 ( ) I am able to walk without help indoors (with or without an appliance), but outdoors and/or on 
stairs only with considerable difficulty or with help from others. 
4 ( ) I am able to walk indoors only with help from others. 
5 ( ) I am completely bed-ridden and unable to move about. 
 
Question 2. Vision 
1 ( ) I see normally, i.e. I can read newspapers and TV text without difficulty (with or 
without glasses). 
2 ( ) I can read papers and/or TV text with slight difficulty (with or without glasses). 
3 ( ) I can read papers and/or TV text with considerable difficulty (with or without glasses). 
4 ( ) I cannot read papers or TV text either with glasses or without, but I can see enough to walk 
about without guidance. 
5 ( ) I cannot see enough to walk about without a guide, i.e. I am almost or completely blind. 
 
Question 3. Hearing 
1 ( ) I can hear normally, i.e. normal speech (with or without a hearing aid). 
2 ( ) I hear normal speech with a little difficulty. 
3 ( ) I hear normal speech with considerable difficulty; in conversation I need voices to be louder 
than normal. 
4 ( ) I hear even loud voices poorly; I am almost deaf. 
5 ( ) I am completely deaf. 
 
Question 4. Breathing 
1 ( ) I am able to breathe normally, i.e. with no shortness of breath or other breathing difficulty. 
2 ( ) I have shortness of breath during heavy work or sports, or when walking briskly on flat ground 
or slightly uphill. 
3 ( ) I have shortness of breath when walking on flat ground at the same speed as others my age. 
4 ( ) I get shortness of breath even after light activity, e.g. washing or dressing myself. 
5 ( ) I have breathing difficulties almost all the time, even when resting. 
 
Question 5. Sleeping 
1 ( ) I am able to sleep normally, i.e. I have no problems with sleeping. 
2 ( ) I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes waking at 
night. 
3 ( ) I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept enough. 
4 ( ) I have great problems with sleeping, e.g. having to use sleeping pills often or routinely, or 
usually waking at night and/or too early in the morning. 
5 ( ) I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of sleeping pills, 
or staying awake most of the night. 
 
Question 6. Eating 
1 ( ) I am able to eat normally, i.e. with no help from others. 
2 ( ) I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with special 
appliances). 
3 ( ) I need some help from another person in eating. 
4 ( ) I am unable to eat by myself at all, so I must be fed by another person. 
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5 ( ) I am unable to eat at all, so I am fed either by tube or intravenously. 
 
Question 7. Speech 
1 ( ) I am able to speak normally, i.e. clearly, audibly and fluently. 
2 ( ) I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or changes of 
pitch. 
3 ( ) I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or 
stammering. 
4 ( ) Most people have great difficulty understanding my speech. 
5 ( ) I can only make myself understood by gestures. 
 
Question 8. Elimination 
1 ( ) My bladder and bowel work normally and without problems. 
2 ( ) I have slight problems with my bladder and/or bowel function, e.g. difficulties with urination, 
or loose or hard bowels. 
3 ( ) I have marked problems with my bladder and/or bowel function, e.g. occasional 'accidents', or 
severe constipation or diarrhoea. 
4 ( ) I have serious problems with my bladder and/or bowel function, e.g. routine 'accidents', or need 
of catheterization or enemas. 
5 ( ) I have no control over my bladder and/or bowel function. 
 
Question 9. Usual activities 
1 ( ) I am able to perform my usual activities (e.g. employment, studying, housework, free-time 
activities) without difficulty. 
2 ( ) I am able to perform my usual activities slightly less effectively or with minor difficulty. 
3 ( ) I am able to perform my usual activities much less effectively, with considerable difficulty, or 
not completely. 
4 ( ) I can only manage a small proportion of my previously usual activities. 
5 ( ) I am unable to manage any of my previously usual activities. 
 
Question 10. Mental function 
1 ( ) I am able to think clearly and logically, and my memory functions well. 
2 ( ) I have slight difficulties in thinking clearly and logically, or my memory sometimes fails me. 
3 ( ) I have marked difficulties in thinking clearly and logically, or my memory is somewhat 
impaired. 
4 ( ) I have great difficulties in thinking clearly and logically, or my memory is seriously impaired. 
5 ( ) I am permanently confused and disoriented in place and time. 
 
Question 11. Discomfort and symptoms 
1 ( ) I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
2 ( ) I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
3 ( ) I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
4 ( ) I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
5 ( ) I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc. 
 
Question 12. Depression 
1 ( ) I do not feel at all sad, melancholic or depressed. 
2 ( ) I feel slightly sad, melancholic or depressed. 
3 ( ) I feel moderately sad, melancholic or depressed. 
4 ( ) I feel very sad, melancholic or depressed. 
5 ( ) I feel extremely sad, melancholic or depressed. 
 
Question 13. Distress 
1 ( ) I do not feel at all anxious, stressed or nervous. 
2 ( ) I feel slightly anxious, stressed or nervous. 
3 ( ) I feel moderately anxious, stressed or nervous. 
4 ( ) I feel very anxious, stressed or nervous. 
5 ( ) I feel extremely anxious, stressed or nervous. 
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Question 14. Vitality 
1 ( ) I feel healthy and energetic. 
2 ( ) I feel slightly weary, tired or feeble. 
3 ( ) I feel moderately weary, tired or feeble. 
4 ( ) I feel very weary, tired or feeble, almost exhausted. 
5 ( ) I feel extremely weary, tired or feeble, totally exhausted. 
 
Question 15. Sexual activity 
1 ( ) My state of health has no adverse effect on my sexual activity. 
2 ( ) My state of health has a slight effect on my sexual activity. 
3 ( ) My state of health has a considerable effect on my sexual activity. 
4 ( ) My state of health makes sexual activity almost impossible. 
5 ( ) My state of health makes sexual activity impossible. 
 
 
 
15D©/Harri Sintonen  
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Appendix 4. Questionnaire of the use of health care services, study V 
 
Please fill out this questionnaire concerning the use of health care services during the last 3 
months. Mark 0 to the place ____ times/day if you have not visited that particular place or have 
not been off from work/studies/school. Mark only separate visits on the questionnaire (for example, 
if you have visited both the doctor’s and nurse’s receptions at the same time, mark only the doctor’s 
visit). 
 
During the last 3 months, how many times have you visited the following places because of your 
salivary gland disorder? 
 
1. the health center of the doctor’s reception? ____ times 
 
2. the occupational physician’s reception? ____ times 
 
3. the nurse’s reception? ____ times 
 
4. the separate laboratory tests? ____ times 
 
5. the hospital policlinic? ____ times 
 
6. the hospital emergency policlinic? ____ times 
 
7. the private doctor’s reception? ____ times 
 
8. the private otorhinolaryngologist’s reception? ____ times 
 
9. During the last 3 months, how many times have you made a phone call to the nurse or 
doctor because of your salivary gland disorder? ____ times 
 
10. During the last 3 months, how many times have you visited a doctor because of some 
reason other than your salivary gland disorder? ____ times 
 
11. How many days have you been off work/studies/school during the last 3 months because 
of your salivary gland disorder? ____ days 
 
12.  How many days have you been in hospital treatment during the last 3 months because 
of your salivary gland disorder? ____ days 
 
 
